US Pat. No. 10,246,732

STABILIZED TEST STRIP FOR THE DETECTION OF HYDROGEN PEROXIDE

PRECISION LABORATORIES, I...

1. A colorimetric dry-reagent test strip for direct detection of the presence of hydrogen peroxide in strongly acidic solutions without the necessity of a neutralization step, consisting essentially of a chromogen responsive to hydrogen peroxide, an enzyme peroxidase catalyst and at least one complexing agent at a concentration that effectively protects an active site of the catalyst for an amount of time sufficient to allow for the catalytic oxidation of the chromogen when contacted with hydrogen peroxide-containing solutions having a pH in the range of 0 to 1, wherein the components are in a dry form on a carrier.
US Pat. No. 10,246,477

ISOMERISATION OF C4-C6 ALDOSES WITH ZEOLITES

DANMARKS TEKNISKE UNIVERS...

1. A method of isomerizing C4-C6 aldoses to their corresponding 2-ketoses, comprising the step ofa) providing
a first solution of one or more C5 aldoses, one or more C6 aldoses, or a mixture thereof in a first solvent, the first solvent being a C1-C3 alcohol or a combination of C1-C3 alcohol and water; or
a second solution of one or more C4 aldoses in a second solvent, the second solvent being water or a combination of C1-C3 alcohol and water and
b) heating the first solution or the second solution in the presence of a solid acidic zeolite catalyst containing aluminum as the only metal (“Zeolite-Al”).
US Pat. No. 10,246,733

ASSAY AND METHOD FOR QUANTITATING CARBONIC ANHYDRASE ACTIVITY AND ASSESSING RED BLOOD HEMOLYSIS

CASE WESTERN UNIVERSITY, ...

1. A method of measuring the amount or activity of carbonic anhydrase enzyme, in a bodily sample, the method comprising:mixing a bodily sample including RBC lysate with a first physiological CO2/HCO3? solution, the first physiological CO2/HCO3? solution having a pH of about 7;
mixing the first physiological CO2/HCO3? solution, which includes the bodily sample, with a second CO2/HCO3? solution, which includes NaHCO3, having a basic dissimilar pH; and
measuring the rate at which the pH of the newly mixed solution equilibrates under the influence of the enzyme to determine carbonic anhydrase activity.
US Pat. No. 10,246,734

SYSTEM AND METHOD FOR DETECTING ALPHA-METHYLACYL-COA RACEMASE (AMACR) AND PROSTATE CANCER

CASE WESTERN RESERVE UNIV...

1. A detection system device for determining alpha-methylacyl-CoA (AMACR) levels in a bodily sample, comprising:at least one reaction solution for generating H2O2 upon combination with AMACR in the bodily sample, the reaction solution including a (2R)-2-methylacyl-CoA epimer that can be chirally inverted by AMACR to a (2S)-2-methylacyl-CoA epimer and peroxisomalacyl-coenzyme A oxidase 3 (ACOX3) that carries out beta oxidation with the (2S)-2-methylacyl-CoA epimer to generate hydrogen peroxide (H2O2);
and a biosensor for determining the level of generated H2O2.
US Pat. No. 10,245,456

PROCESS FOR DECONTAMINATION AND DETOXIFICATION WITH ZIRCONIUM HYDROXIDE-BASED SLURRY

The United States of Amer...

1. A process for decontaminating surfaces contaminated with at least one toxic agent, comprising applying onto said contaminated surfaces a decontamination composition comprising an aqueous or non-aqueous carrier liquid and at least two types of Zr(OH)4 including a first type Zr(OH)4 and a second type Zr(OH)4, wherein said first type Zr(OH)4 has an average particle size of up to 100 nm and said second type Zr(OH)4 has an average particle size of at least 10 ?m, and wherein said decontamination composition has a weight ratio of said first type Zr(OH)4 to said second type Zr(OH)4 in the range of about 5:1 to 2:1.
US Pat. No. 10,246,736

METHODS AND APPARATUSES FOR NUCLEIC ACID SHEARING BY SONICATION

Life Technologies Corpora...

1. A method for preparing a gene fragment library, the method comprising:a) providing a suspension comprising a sample of purified genomic nucleic acid and monodisperse particles, wherein the suspension is an aqueous solution without nonaqueous solvent:
b) sonicating the suspension, thereby generating nucleic acid fragments:
c) collecting the nucleic acid fragments; and
d) preparing a gene fragment library by ligating the nucleic acid fragments to nucleic acid adaptors.
US Pat. No. 10,246,737

METHODS FOR DETECTING MULTIPLE NUCLEIC ACIDS IN A SAMPLE USING REPORTER COMPOUNDS AND BINDING MEMBERS THEREOF

ALERE TECHNOLOGIES GMBH, ...

1. A method of determining the presence and/or amount of nucleic acids in a sample, comprising(a) introducing into a reaction chamber
an amount of a first nucleic acid;
an amount of a second nucleic acid;
an amount of a FRET compound capable of forming complexes with the first nucleic acid, wherein the FRET compound comprises a binding portion specific to a region of the first nucleic acid, and a first detectable label that has, in an uncomplexed state, a first detectable characteristic and, in a complexed state, a second detectable characteristic;
an amount of a reporter compound capable of forming complexes with the second nucleic acid, wherein each reporter compound comprises a binding portion specific to a region of the second nucleic acid and a second detectable label, wherein said second detectable label is identical to said first detectable label; and
wherein the reaction chamber comprises a binding member capable of capturing the reporter compound;
wherein forming of complexes of the second nucleic acid with the reporter compound inhibits capturing of the reporter compound by the binding member;
(b) subjecting the first and/or second nucleic acid to amplification;
(c) forming complexes each comprising a first nucleic acid and a FRET compound;
(d) forming complexes of a subset of the amount of reporter compound with a second nucleic acid;
(e) capturing a remaining subset of the amount of reporter compound not in complex with a second nucleic acid on the binding member;
(f) determining a value indicative for the presence and/or amount of first nucleic acid in complex with FRET compounds; and
(g) determining a value indicative for the presence and/or amount of reporter compound captured on the binding member.
US Pat. No. 10,244,691

ROOT-KNOT NEMATODE RESISTANCE MARKER FOR TOMATO PLANT, ROOT-KNOT NEMATODE RESISTANT TOMATO PLANT, PRODUCTION METHOD FOR ROOT-KNOT NEMATODE RESISTANT TOMATO PLANT, AND SCREENING METHOD FOR ROOT-KNOT NEMATODE RESISTANT TOMATO PLANT

1. A method of producing a root-knot nematode resistant tomato plant, the method comprising:detecting, in one or more tomato plants to be examined,
marker TY38 corresponding to the 21st nucleotide of SEQ ID NO: 22to identify a root-knot nematode resistance locus on chromosome 4 and select a root-knot nematode resistant tomato plant comprising the marker, andcrossing the root-knot nematode resistant tomato plant comprising the root-knot nematode resistance locus on chromosome 4 with a cultivated tomato plant to produce a progeny plant, wherein the progeny plant has the root-knot nematode resistance locus on chromosome 4.
US Pat. No. 10,246,484

METHOD FOR PURIFYING RECOMBINANT PROTEIN

SUNSHINE GUOJIAN PHARMACE...

1. A method for purifying a recombinant protein from a mixture comprising the recombinant protein and its related proteins, which comprises the following steps performed sequentially:A. binding the recombinant protein to an ion exchange medium using a first equilibration buffer, wherein the first equilibration buffer is at a first conductivity and pH;
the ion exchange medium is a cation exchange medium;
B. equilibrating the protein-bound ion exchange medium continually using a second equilibration buffer, wherein the second equilibration buffer is at a second conductivity and pH;
the conductivity of the second equilibration buffer is less than that of the first equilibration buffer, but the pH of both are the same;
C. washing the ion exchange medium using a wash buffer which has different pH, so as to elute a first class of the related proteins from the ion exchange medium, wherein the wash buffer is at a third conductivity and a gradually increased pH;
the conductivity of the wash buffer is less than that of the first equilibration buffer, but the pH of the wash buffer is greater than that of the first and/or second equilibration buffer;
D. washing the ion exchange medium using a first elution buffer, so as to elute the target recombinant protein from the ion exchange medium, wherein the first elution buffer is at a fourth conductivity and pH;
the pH of the first elution buffer is greater than that of the wash buffer, but the conductivity of both are essentially the same; and
E. then washing the ion exchange medium using a second elution buffer, so as to elute a second class of related proteins from the ion exchange medium, wherein the second elution buffer is at a fifth conductivity and pH;
the pH and/or conductivity of the second elution buffer are/is greater than that of the first elution buffer.
US Pat. No. 10,248,020

ACID GENERATORS AND PHOTORESISTS COMPRISING SAME

Rohm and Haas Electronic ...

14. A photoresist composition, comprising:(i) a polymer;
(ii) a first non-polymeric onium salt acid generator that produces a first acid upon exposure of the photoresist composition to activating radiation; and
(iii) a second onium salt acid generator that 1) comprises a covalently bound acid-labile moiety and 2) produces a second acid upon exposure of the photoresist composition to activating radiation;
wherein the first acid and second acid have pKa values that differ by at least 1;
wherein at least one of the first onium salt acid generator and the second onium salt acid generator comprises a thioxanthone moiety; and
wherein the first onium salt acid generator and the second onium salt acid generator are each not bound to a polymer.
US Pat. No. 10,244,693

HYBRID TOMATO VARIETY 72-759 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum tomato plant designated variety 72-759 RZ, representative seed of which having been deposited under NCIMB Accession No. 42682.
US Pat. No. 10,246,485

METHOD TO CONCENTRATE VON WILLEBRAND FACTOR OR COMPLEXES THEREOF

CSL LIMITED, Parkville (...

1. A method for concentrating von Willebrand Factor (VWF) from an aqueous solution comprising the steps of(a) precipitating the VWF by adding calcium ions and phosphate ions to the aqueous solution,
(b) separating the precipitate formed in step (a), and
(c) resolubilizing the precipitate isolated in step (b) by contacting the precipitate with an aqueous solution comprising a calcium complexing agent, wherein
the VWF comprises a full-length VWF polypeptide.
US Pat. No. 10,248,021

POLYMER AND POSITIVE RESIST COMPOSITION

ZEON CORPORATION, Chiyod...

4. A positive resist composition comprising the polymer according to claim 1 and a solvent.
US Pat. No. 10,244,694

HYBRID TOMATO PLANT NAMED 58811

HM.CLAUSE, INC., Davis, ...

1. A seed of hybrid tomato designated 58811, wherein a representative sample of seed of said hybrid has been deposited under NCIMB No. 42749.
US Pat. No. 10,244,695

TOMATO HYBRID SV6133TM AND PARENTS THEREOF

SEMINIS VEGETABLE SEEDS, ...

1. A tomato seed of tomato hybrid SV6133TM, a sample of seed of said hybrid SV6133TM having been deposited under ATCC Accession Number PTA-122352.
US Pat. No. 10,244,696

HYBRID TOMATO VARIETY H1538

H.J. Heinz Company Brands...

1. Tomato seed designated as ‘H1538’, representative sample of seed having been deposited under ATCC Accession Number PTA-124277.
US Pat. No. 10,246,488

USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES

Yeda Research and Develop...

1. An isolated peptide comprising an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1(PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
US Pat. No. 10,246,744

METHOD AND SYSTEM FOR SEQUENCING NUCLEIC ACIDS

OMNIOME, INC., San Diego...

16. A method of sequencing a primed template nucleic acid, comprising:(a) contacting a primed template nucleic acid with a polymerase and a first combination of two and only two or three and only three types of test nucleotides under conditions that form a stabilized ternary complex between the polymerase, primed template nucleic acid and a test nucleotide that is complementary to the next base of the primed template nucleic acid;
(b) detecting the ternary complex while precluding incorporation of test nucleotides into the primer;
(c) repeating steps (a) and (b) using the primed template nucleic acid, a polymerase and a second combination of two or three types of test nucleotides, wherein the second combination is different from the first combination;
(d) incorporating into the primer, after step (c), a nucleotide that is complementary to the next base; and
(e) repeating steps (a) through (d) to identify a sequence of the primed template nucleic acid.
US Pat. No. 10,248,792

DETECTION AND HEALING OF VULNERABILITIES IN COMPUTER CODE

BlueRISC, Inc., Amherst,...

1. A method performed by one or more processing devices, comprising:during compilation of computer code by the one or more processing devices:
performing a static analysis of the computer code to identify a memory instruction in the computer code that constitutes a potential vulnerability in the computer code, the memory instruction comprising a memory store instruction that is repeatable and that uses contiguous memory during a repetition; and
inserting a healing template into the computer code at a location that is based on the potential vulnerability, the healing template being generic to a class of vulnerabilities; and
during execution of the computer code by the one or more processing devices:
updating the healing template based on an attack that occurred at the potential vulnerability, the healing template for inhibiting one or more subsequent attacks that occur at the potential vulnerability; and
using the healing template to inhibit the one or more subsequent attacks.
US Pat. No. 10,244,697

COTTON VARIETY PX2048-04WRF

Phyotogen Seed Company, L...

1. A seed of cotton variety designated PX2048-04WRF, or a regenerable part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-122544.
US Pat. No. 10,244,698

COTTON VARIETY PHY764WRF

Phytogen Seed Company, LL...

1. A seed of cotton variety designated PHY764WRF, or a regenerable part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-122543.
US Pat. No. 10,246,490

CONOTOXIN PEPTIDE ?-CPTX-BTL02, PREPARATION METHOD THEREFOR, AND USES THEREOF

BGI SHENZHEN, Guangdong ...

1. A method of inhibiting a calcium ion channel, the method comprising contacting the calcium ion channel with a conotoxin peptide ?-CPTx-btl02, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, and wherein the peptide contains three pairs of disulfide bonds.
US Pat. No. 10,246,746

PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES

Illumina, Inc., San Dieg...

1. A method of sequencing a target nucleic acid polymer, comprising:(a) modifying a target nucleic acid polymer to produce a modified nucleic acid polymer, wherein the modified nucleic acid polymer comprises a plurality of sequence regions from the target nucleic acid polymer;
(b) releasing fragments of the modified nucleic acid polymer onto a solid support surface, each fragment comprising one of the sequence regions;
(c) capturing the fragments randomly at locations in an area of the solid support surface;
(d) determining nucleotide sequences of the sequence regions by detecting the fragments at the locations;
(e) determining relative physical distances between the fragments at the locations; and
(f) producing a representation of the nucleotide sequence for the target nucleic acid polymer based on the nucleotide sequences from the fragments and the determined relative physical distances between the locations on the solid support surface, wherein the relative physical distances are indicative of distances between the sequence regions along a given strand of the target nucleic acid polymer.
US Pat. No. 10,244,699

SOYBEAN VARIETY 5PNJE71

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PNJE71, representative seed of the variety having been deposited under ATCC Accession Number PTA-125150.
US Pat. No. 10,246,235

PACKAGING FILM

1. A packing film comprising an unembossed multilayer polymeric film having a total thickness ?18 ?m, which is oriented at least monoaxially in machine direction to an orientation ratio of at least 1:2, which comprises at least to an extent of 50 wt % polyethylenes (PE), polypropylenes (PP), their mixtures or copolymers,which comprises a layer sequence of at least five layers composed of
a) a layer (a) as surface layer comprising a mixture of LDPE and MDPE or a mixture of LDPE, MDPE and PP,
b) an adhesion promoter layer (b),
c) a layer (c), based on a mixture of LDPE and MDPE or a mixture of LDPE, MDPE and PP or ethylene/vinyl alcohol copolymers, polyvinyl alcohols, polyamides, copolyamides, polyesters and/or polyether-polyamide block copolymers,
d) an adhesion promoter layer (d), and
e) a layer e) as surface layer comprising a mixture of LDPE and MDPE or a mixture of LDPE, MDPE and PP,
and which has an elongation of up to at most 1% under a tensile force of at least 3 N per 25 mm width in accordance with DIN EN ISO 527-3 and has no embossed structure on its surface layers.
US Pat. No. 10,246,747

METHODS OF USING MIRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)

DiamiR, LLC, Princeton, ...

1. A method for identifying a compound useful for slowing down the progression of or treating pre-MCI or MCI, which method comprises:a. measuring the level of at least one synapse or neurite miRNA in one or more bodily fluid samples collected from a subject having pre-MCI or MCI, wherein the synapse or neurite miRNA is selected from the group consisting of miR-7, miR-125b, miR-128, miR-132, miR-874, miR-134, miR-323-3p, and miR-382, wherein said bodily fluid sample(s) is collected prior to test compound administration and wherein the bodily fluid is selected from the group consisting of blood plasma, serum, urine, and saliva;
b. measuring the level of a normalizer miRNA in the same bodily fluid sample(s) as in step (a), wherein the normalizer miRNA is selected from the group consisting of miR-9, miR-181a, miR-127-3p, miR-370, miR-141, and miR-491-5p;
c. calculating the ratio of the level of the synapse or neurite miRNA measured in step (a) to the level of the normalizer miRNA measured in step (b) for each of the bodily fluid samples collected from the subject prior to a test compound administration;
d. measuring the level of the same synapse or neurite miRNA(s) as in step (a) in one or more bodily fluid samples collected from the subject following administration of the test compound, wherein the bodily fluid is selected from the group consisting of blood plasma, serum, urine, and saliva;
e. measuring the level of the same normalizer miRNA as in step (b) in the same bodily fluid sample(s) as in step (d);
f. calculating the ratio of the level of the synapse or neurite miRNA measured in step (d) to the level of the normalizer miRNA measured in step (e) for each of the bodily fluid samples collected from the subject following administration of the test compound;
g. comparing the ratios of the levels of the miRNAs calculated in steps (c) and (f), and
h. (i) identifying the test compound as a candidate compound for slowing down the progression of or treating pre-MCI or MCI if the ratio of the levels of the miRNAs calculated in step (f) is lower than the ratio of the levels of the miRNAs calculated in step (c); (ii) identifying the test compound as not a candidate compound for slowing down the progression of or treating pre-MCI or MCI if the ratio of the levels of the miRNAs calculated in step (f) is not lower than the ratio of the levels of the miRNAs calculated in step (c).
US Pat. No. 10,244,700

SOYBEAN VARIETY 5PBDN11

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PBDN11, representative seed of the variety having been deposited under ATCC Accession Number PTA-125151.
US Pat. No. 10,246,492

BOTULINUM ASSAY WITH SYNAPTOBREVIN SUBSTRATE MOIETY

BIOMADISON, INC., Del Ma...

1. A recombinant nucleic acid comprising:a sequence that encodes a first hybrid proteins having a structure of A-C-B and a second hybrid protein having a structure of A-C? D;
wherein A is a transmembrane protein domain of synaptobrevin targeted to an intracellular vesicle membrane and is not cleavable by a Botulinum neurotoxin protease, B is a first fluorescent protein, C is a first linking domain comprising a Botulinum neurotoxin protease recognition sequence and a Botulinum neurotoxin protease cleavage sequence, C? is a second linking domain comprising an analog of C that includes the Botulinum neurotoxin protease recognition sequence but not the Botulinum neurotoxin protease cleavage sequence, and D is a second fluorescent protein selected to form a Förster resonance energy transfer (FRET) pair with the first fluorescent protein, wherein said transmembrane domain, said peptide spacer, and said BoNT protease recognition and cleavage sequence are selected to support FRET between said first fluorescent protein and said second fluorescent protein when said first hybrid protein and said second hybrid protein are collocated with a vesicle.
US Pat. No. 10,246,748

BIOMARKER COMBINATIONS FOR COLORECTAL TUMORS

NOVIGENIX SA, Epalinges ...

1. A method for detecting IL1B, PTGS2 and at least one of S100A8, LTF, CXCL10, and CACNB4, the method comprising:(a) extracting RNA from blood cells in peripheral blood from a selected subject to produce extracted RNA; and
(b) measuring in the extracted RNA the amount of mRNA for each biomarker in one biomarker panel, wherein the biomarker panel consists of from 3 to 29 biomarkers, wherein the 3 to 29 biomarkers comprise IL1B, PTGS2, and at least one of S100A8, LTF, CXCL10, and CACNB4,
wherein said method does not comprise measuring more than 29 biomarkers.
US Pat. No. 10,249,821

FORMATION AND STRUCTURE OF LYOTROPIC LIQUID CRYSTALLINE MESOPHASES IN DONOR-ACCEPTOR SEMICONDUCTING POLYMERS

THE REGENTS OF THE UNIVER...

1. A composition of matter, comprising:lyotropic semiconducting polymers each having a donor-acceptor copolymer backbone and a side chain attached to the backbone, wherein the donor-acceptor copolymer backbone comprises fused aromatic rings.
US Pat. No. 10,244,701

SWEET CORN HYBRID SVSD7749 AND PARENTS THEREOF

SEMINIS VEGETABLE SEEDS, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SYY6S-14NN18, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124217.
US Pat. No. 10,246,493

DE NOVO STRUCTURAL PROTEIN DESIGN FOR MANUFACTURING HIGH STRENGTH MATERIALS

The Penn State Research F...

1. A method of making a synthetic or recombinant polypeptide capable of forming at least a first crystal-forming domain block and at least a first amorphous domain block, the method comprising selecting an amino acid sequence that is capable of forming the first crystal domain block, wherein the crystal domain block is from about 2 nm to about 5 nm long and comprises from 10 to 30 amino acids, and selecting an amino acid sequence that is capable of forming a first amorphous domain block, wherein the first amorphous domain block is about 3 nm long and comprises about 15 amino acids, and forming the synthetic or recombinant polypeptide by incorporating [i] the amino acid sequence comprising AA[XXXXXX]HH (SEQ ID NO: 313), wherein the XXXXXX comprises histidine, threonine, valine, alanine, serine, or a combination thereof that is capable of forming the first crystal-forming domain block and [ii] the amino acid sequence comprising a glycine rich sequence according to Table 6 that is capable of forming the first amorphous domain block into the synthetic or recombinant polypeptide.
US Pat. No. 10,246,749

METHOD FOR DIAGNOSING BREAST CANCER

Albert-Ludwigs-Universita...

1. A method of diagnosing a subject with breast cancer, said method comprising the steps of:a. detecting and measuring the levels of the following four miR gene products: miR-21, miR125b, miR-451, and miR-155 in a cell-free test sample isolated from a whole urine sample obtained from said subject;
b. comparing the respective levels of each of said four miR gene products in the subject test sample detected and measured in step (a) with its corresponding miR gene product control level in a control sample; and
c. diagnosing with breast cancer the subject for whom the comparison of step (b) reveals a decrease in the respective levels of miR-21, miR-125b, and miR-451, and an increase in the level of miR-155 in the subject test sample measured in step (a) as compared to each corresponding control level,
wherein said cell-free test sample is a supernatant isolated from the whole urine sample, wherein the whole urine sample has been processed to eradicate contamination with any urothelial or microbiological cell material.
US Pat. No. 10,244,702

HYBRID CORN VARIETY 15711553

Agrigenetics, Inc., Indi...

1. A seed of the hybrid corn variety 15711553, produced by crossing a first plant of variety 3EESL0003 with a second plant of variety XHE06, wherein representative seed of said varieties 3EESL0003 and XHE06 have been deposited under ATCC Accession numbers PTA-123410 and PTA-12583, respectively.
US Pat. No. 10,245,470

GOLF BALL COMPOSITIONS COMPRISING THERMOPLASTIC POLYURETHANE IONOMERS

Acushnet Company, Fairha...

1. A golf ball comprising:an inner core layer having an outer surface hardness of 85 Shore C or less and formed from a thermoplastic polyurethane ionomer composition,
an outer core layer having an outer surface hardness of 50 Shore C or greater and formed from a thermoset rubber composition, and
a cover;
wherein the thermoplastic polyurethane ionomer composition of the inner core layer includes an ionic monomer covalently bonded to the polyurethane ionomer backbone, and wherein the ionic monomer comprises a sulfonate containing polyol ion and a quaternary ammonium counterion; and
wherein the outer surface hardness of the outer core layer is greater than the outer surface hardness of the inner core layer.
US Pat. No. 10,246,494

POLYPEPTIDES AND ANTIBODIES FOR TREATING HBV INFECTION AND RELATED DISEASES

Xiamen University, Xiame...

1. A monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody specifically binds to positions 119 to 125 of HBsAg protein of HBV, and is selected from one of the following monoclonal antibodies:1) the monoclonal antibody produced by the hybridoma cell line HBs-E6F6, wherein the hybridoma cell line HBs-E6F6 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO. C201270;
2) the monoclonal antibody produced by the hybridoma cell line HBs-E7G11, wherein the hybridoma cell line HBs-E7G11 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO. C201271;
3) the monoclonal antibody produced by the hybridoma cell line HBs-G12F5, wherein the hybridoma cell line HBs-G12F5 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO. C201272;
4) the monoclonal antibody produced by the monoclonal antibody produced by hybridoma cell line HBs-E13C5, wherein the hybridoma cell line HBs-E13C5 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO. C201273 and
5) the monoclonal antibody or an antigen binding fragment selected from a humanized antibody, a chimeric antibody or a single chain antibody made from any of the monoclonal antibodies as described in 1-4 above.
US Pat. No. 10,246,750

METHOD FOR DETECTION OF A TECR:PKN1 OR AN ANXA4:PKN1 GENE FUSION

Blueprint Medicines Corpo...

1. A method for detecting in a patient a Protein Kinase N1 (PKN1) fusion that results in aberrant activity or expression of PKN1 or overexpression of PKN1, wherein the PKN1 fusion is a Trans-2,3-enoyl-CoA reductase (TECR):PKN1 or Annexin A4 (ANXA4):PKN1 fusion, said method comprising:a) contacting a biological sample obtained from the patient with an oligonucleotide that hybridizes to the fusion junction of a PKN1 gene fusion; and
b) detecting binding between the PKN1 gene fusion and the oligonucleotide.
US Pat. No. 10,244,703

INBRED CORN LINE 3EESL0003

Agrigenetics, Inc., Indi...

1. Seed of corn inbred line designated 3EESL0003, or a part thereof, representative seed of the line having been deposited under ATCC Accession No. PTA-123410.
US Pat. No. 10,246,495

VARIANTS OF GAL2 TRANSPORTER AND THEIR USES

1. A polypeptide comprising at least one amino acid substitution at a position corresponding to T354 of the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide has at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1, and wherein the polypeptide has an in vitro and/or in vivo pentose transport function.
US Pat. No. 10,246,751

METHOD FOR DISCRIMINATION OF METAPLASIAS FROM NEOPLASTIC OR PRENEOPLASTIC LESIONS

VENTANA MEDICAL SYSTEMS, ...

1. A method for screening a uterine cervical cytology sample, comprising:(a) obtaining at least one slide having the uterine cervical cytology sample deposited thereon;
(b) staining the uterine cytology sample with a labeled oligonucleotide probe that specifically binds p16INK4a mRNA and is complementary to p16INK4a mRNA in the sample by in situ hybridization, wherein the label of the oligonucleotide probe that is complementary to the p16INK4a mRNA generates a first reporter signal;
(c) staining the uterine cervical cytology sample with a labelled oligonucleotide probe that specifically binds a high risk HPV (hr-HPV) gene-product and is complementary to a mRNA of the high risk HPV (hr-HPV) gene-product by in situ hybridization, wherein said high risk HPV gene-product is encoded by a gene selected from the group consisting of HPV E7 gene, HPV E2 gene, HPV E6 gene, HPV L1 gene, and HPV L2 gene, wherein the label of the oligonucleotide probe that is complementary to the mRNA of the hr-HPV gene product generates a second reporter signal; and
(d) detecting in the uterine cytology sample:
(d1) the simultaneous-presence of cells stained with the label generating the first reporter signal and cells stained with the label generating the second reporter signal, or
(d2) the presence of cells stained with the label generating the first reporter signal and the absence of cells stained with the label generating the second reporter signal.
US Pat. No. 10,244,704

SOYBEAN VARIETY 01068084

MONSANTO TECHNOLOGIES LLC...

1. A plant of soybean variety 01068084, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124739.
US Pat. No. 10,246,496

POTASSIUM CHANNEL BLOCKERS AND USE THEREOF IN THE TREATMENT OF AUTOIMMUNE DISEASES

LA TROBE UNIVERSITY, (AU...

1. An analogue of Stichodactyla helianthus toxin ShK comprising an ShK toxin polypeptide and an N-terminal extension selected from the group consisting ESSS (SEQ ID NO: 1), EWSS (SEQ ID NO: 2), EESS (SEQ ID NO: 5), EWST (SEQ ID NO: 6), EWTT (SEQ ID NO: 7), EWTS (SEQ ID NO: 8) and SEWSS (SEQ ID NO: 9).
US Pat. No. 10,246,752

METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS

Adaptive Biotechnologies ...

1. A method for quantitatively measuring clonotypes correlating to a disease state of a subject wherein the disease is a cancer, wherein the method comprises:(a) identifying a sequence and level of the clonotype correlated with the disease in the subject, comprising
(1) generating and comparing a first clonotype profile from a first sample taken from the subject and a second clonotype profile from a second sample taken from the subject, wherein the first sample and the second sample each comprises T-cells and/or B-cells from the subject and are taken at different times from the subject, wherein each clonotype profile is generated by a method comprising:
(i) isolating genomic DNA from the first and second samples;
(ii) amplifying from said isolated genomic DNA recombined DNA sequences of the T-cells and/or B-cells in a multiplex PCR, comprising hybridizing to the genomic DNA a plurality of primers; wherein the regions to be amplified comprise V, D, and/or J segments of an immunoglobulin and/or a T-cell or B-cell receptor gene;
(iii) spatially isolating individual molecules of the amplified sequences on a solid substrate, wherein the solid substrate is a glass slide; and
(iv) sequencing said amplified individual molecules to produce the clonotype profile by sequencing by synthesis using reversibly terminated labeled nucleotides;
(2) comparing the generated first and second clonotype profiles to identify the presence and level of the clonotype correlated with the disease in the subject; and
(b) producing a quantitative profile of clonotyes identified in step (a)(2) that correlate with the disease in the subject, wherein the profile comprises sequences and levels of said clonotypes.
US Pat. No. 10,244,705

SOYBEAN VARIETY 01064265

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01064265, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124747.
US Pat. No. 10,246,497

SELECTIVE PYY COMPOUNDS AND USES THEREOF

1. A PYY compound comprising tryptophan at the position corresponding to position 30 of hPYY(1-36) (SEQ ID NO:1), a maximum of 8 amino acid modifications as compared to hPYY(3-36), wherein the PYY compound comprises N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY(1-36) (SEQ ID NO:1), and wherein the positions corresponding to positions 1-2 or 1-3 of hPYY(1-36) (SEQ ID NO:1) are absent, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,246,753

METHOD AND SYSTEM FOR CHARACTERIZING MOUTH-ASSOCIATED CONDITIONS

uBiome, Inc., San Franci...

1. A system for evaluating a mouth-associated condition in relation to a user, the system comprising:a handling network operable to collect containers comprising material from a set of users, the handling network comprising:
a library preparation system operable to fragment and perform multiplex amplification on the material using a primer compatible with a genetic target associated with the mouth-associated condition;
a sequencing system operable to determine microorganism sequences from sequencing the material;
a microbiome characterization system operable to:
determine microbiome composition data and microbiome functional diversity data based on an alignment between the microorganism sequences and reference sequences associated with the mouth-associated condition,
collect supplementary data associated with the mouth-associated condition for the set of users, and
transform the supplementary data and features extracted from the microbiome composition data and the microbiome functional diversity data into a characterization model for the mouth-associated condition; and
a treatment system operable to provide a treatment to the user based on characterizing the user with the characterization model in relation to the mouth-associated condition.
US Pat. No. 10,244,706

SOYBEAN VARIETY 01064571

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01064571, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124755.
US Pat. No. 10,245,218

CORE-SHELL TYPE POLYMER PARTICLE, AQUEOUS POLYMER EMULSION, AND HAIR COSMETIC COMPOSITION

MITSUBISHI CHEMICAL CORPO...

1. An aqueous polymer emulsion, comprising a core-shell type polymer particle dispersed in water,wherein the core-shell type polymer particle comprises a shell part composed of an amphoteric ion polymer (A) and a core part composed of a hydrophobic polymer (B).
US Pat. No. 10,246,498

GENETICALLY ENCODED HISTONE REPORTER ALLELE CONSTRUCTS

The Johns Hopkins Univers...

1. A fusion protein reporter comprising:a) a histone-modification-specific binding domain that is configured to bind to said histone polypeptide substrate when said histone polypeptide substrate is modified;
b) a histone polypeptide substrate; and
c) a flexible linker region, wherein the flexible linker region is flanked on one side by a region encoding a C-terminal portion of a circularly permutated fluorescent protein and on the other side by a region encoding the N-terminal portion of the circularly permutated fluorescent protein, and wherein said C-terminal portion of said circularly permutated fluorescent protein and said N-terminal portion of said circularly permutated fluorescent protein form a functional fluorescent protein when said histone-modification-specific binding domain binds to said histone polypeptide substrate.
US Pat. No. 10,246,754

MOLECULAR MARKERS LINKED TO DISEASE RESISTANCE IN SOYBEAN

Syngenta Participations A...

1. A method of producing a soybean plant having an Asian soybean rust (ASR) resistance, the method comprising the steps of:a) isolating a nucleic acid from a soybean plant cell;
b) detecting in the nucleic acid of a) the presence of a haplotype associated with an ASR resistance allele, wherein said haplotype comprises a C at nucleotide 1 of SEQ ID NO: 1, a G at nucleotide 14 of SEQ ID NO: 1, a T at nucleotide 51 of SEQ ID NO: 1, a G at nucleotide 59 of SEQ ID NO: 1, a C at nucleotide 143 of SEQ ID NO: 1, a G at nucleotide 148 of SEQ ID NO: 1, and an A at nucleotide 157 of SEQ ID NO: 1;
c) identifying a first soybean plant on the basis of the presence of the haplotype detected in b);
d) crossing the first soybean plant with a second soybean plant not comprising said haplotype; and
e) producing a progeny plant from the cross of d), wherein said progeny plant comprises the haplotype detected in b), thereby producing a soybean plant having ASR resistance.
US Pat. No. 10,244,707

WHEAT VARIETY W070474I1

PIONEER HI-BRED INTERNATI...

1. A plant, plant part, seed, or plant cell of wheat variety W070474I1, representative seed of said variety having been deposited under ATCC accession number PTA-123444.
US Pat. No. 10,246,755

CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE

Allena Pharmaceuticals, I...

1. A pharmaceutical composition comprising a capsule containing crystals of spray-dried oxalate decarboxylase comprising the amino acid sequence of SEQ ID NO:1 where the thiol moiety at Cys383 is protected by a reaction with a thiol protecting group, wherein the crystals have a Hausner ratio of about 1.00 to about 1.59.
US Pat. No. 10,244,708

SOYBEAN VARIETY 01064594

Monsanto Technology LLC, ...

1. A plant of soybean variety 01064594, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124891.
US Pat. No. 10,246,500

HUMAN CYTOLYTIC FUSION PROTEINS

The University of Cape To...

1. A recombinant human cytolytic fusion protein (hCFP) suitable to induce apoptosis in human target cells, comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64, and the effector domain comprises a variant or a functional fragment of wild type human angiogenin (Ang) as shown in SEQ ID NO: 1, wherein the variant of the wild type human angiogenin as shown in SEQ ID NO: 1 contains at least substitutions at positions that correspond structurally or by amino acid sequence homology to positions 85, 86 and 117, and wherein the substitutions are G85R, G86R and Q117G.
US Pat. No. 10,248,036

POSITIVELY CHARGEABLE TONER

KYOCERA Document Solution...

7. A positively chargeable toner comprisinga plurality of toner particles each including a toner mother particle and external additives adhering to a surface of the toner mother particle, wherein
the toner particles each include a silica particle as one of the external additives and a titania particle as another one of the external additives, the silica particle having on a surface thereof an alkyl group having a carbon number of at least 8 and no greater than 16 and an amino group, the titania particle having an amino group on a surface thereof,
the titania particle has a volume resistivity of at least 1.0×109 ?·cm and no greater than 1.0×1011 ?·cm,
the silica particles have a number average primary particle diameter larger than that of the titania particles, and
the silica particle has a volume resistivity of at least 1.0×1014 ?·cm and no greater than 1.0×1016 ?·cm.
US Pat. No. 10,244,709

SOYBEAN CULTIVAR S170008

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170008, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124445.
US Pat. No. 10,246,501

FUSION POLYPEPTIDES AND METHODS OF USE

Prosit Sole Biotechnology...

1. A fusion polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3-19.
US Pat. No. 10,246,757

BEARING PART

1. A bearing part comprising, as a chemical composition, by mass %,C: 0.95% to 1.10%,
Si: 0.10% to 0.70%,
Mn: 0.20% to 1.20%,
Cr: 0.90% to 1.60%,
Al: 0.010% to 0.100%,
N: 0.003% to 0.030%,
P: 0.025% or less,
S: 0.025% or less,
O: 0.0010% or less, and
optionally
Mo: 0.25% or less,
B: 0.0050% or less,
Cu: 1.0% or less,
Ni: 3.0% or less, and
Ca: 0.0015% or less, and
a remainder including Fe and impurities,
wherein a metallographic structure includes a retained austenite, a spherical cementite and a martensite,
wherein an amount of the retained austenite is 15% to 25%, by volume %,
wherein an average grain size of a prior-austenite is 8.0 ?m or less, and
wherein a number density of a void having a circle equivalent diameter of 0.02 ?m to 3.0 ?m is 2000 mm?2 or less in the metallographic structure.
US Pat. No. 10,248,037

DEVELOPER, DEVELOPER STORAGE BODY, DEVELOPING DEVICE AND IMAGE FORMING APPARATUS

Oki Data Corporation, To...

1. A developer comprising developer particles, each of the developer particles comprising:a binder resin;
a brilliant pigment whose principal component is aluminum;
a yellow pigment;
a magenta pigment;
a reddish-orange fluorescent dye; and
a yellow fluorescent dye,
wherein when an average particle diameter of the brilliant pigments included in the developer particles is expressed as D (?m), a number proportion of the developer particles having particle diameters in a range from 4 ?m to 1.2×D ?m in whole developer particles is less than or equal to 4%.
US Pat. No. 10,244,710

SOYBEAN CULTIVAR S170003

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170003, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-11124446.
US Pat. No. 10,245,222

DENTIFRICE COMPRISING ZINC-AMINO ACID COMPLEX

Colgate-Palmolive Company...

1. A dentifrice comprising a zinc-amino acid-halide complex, wherein the amino acid is lysine, and complex is a zinc lysine chloride complex having the chemical structure [Zn(C6H14N2O2)2Cl]+Cl?, either in solution of the cation [Zn(C6H14N2O2)2Cl]+ and the chloride anion, or in solid salt form, optionally in mono- or dihydrate form.
US Pat. No. 10,246,502

IL22 IMMUNOCONJUGATES

Philogen S.P.A., Siena (...

1. A conjugate comprising interleukin-22 (IL22) and an antibody molecule, wherein the antibody molecule comprises an antigen-binding site which binds the Extra Domain-A (ED-A) of fibronectin and comprises the complementarity determining regions (CDRs) of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO: 11.
US Pat. No. 10,246,758

METHOD FOR PRODUCING A COMPONENT FROM STEEL BY HOT FORMING

SALZGITTER FLACHSTAHL GMB...

1. A method for the production of a component from transformable steel, comprising the steps in the order of:cutting to size a blank as source material from a strip or metal sheet;
austenitizing and quenching the blank such as to produce a partly martensitic transformation microstructure and a residual austenite microstructure, by heating the blank to an austenitizing temperature within a continuous annealing process and subsequently quenching the blank;
applying a coating on the blank by a hot dip process after the annealing process;
reheating the blank to a forming temperature below the Ac1 transformation temperature, while maintaining the partly martensitic transformation microstructure and the residual austenite microstructure; and
forming the blank at the forming temperature below the Ac1 transformation temperature into the component while still maintaining the partly martensitic transformation microstructure and the residual austenite microstructure in the component.
US Pat. No. 10,244,711

SOYBEAN CULTIVAR S170024

M.S. TECHNOLOGIES, LLC, ...

1. A plant of soybean cultivar S170024, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124464.
US Pat. No. 10,246,503

METHOD OF IMPROVING THE PHARMACOKINETIC PROFILE OF A THERAPEUTIC POLYPEPTIDE AND THE USE THEREOF

BEIJING ANXINHUAIDE BIOTE...

1. A fusion protein comprising a therapeutic polypeptide (TP) fused to one or more pCloud sequences and a scaffold protein,wherein TP is human glucagon-like peptide or a functional variant thereof,
the scaffold protein forms a homo-trimer in solution and is selected from the group consisting of human collagen noncollagenous (NC) domains which form stable homo-trimers in solution, and
the pCloud sequence is a flexible un-structured polypeptide comprising some or all of the fragments of the human fibrinogen alpha chain; and
wherein the pCloud polypeptide sequence:
(a) comprises at least 100 to about 3000 amino acid residues;
(b) comprises some or all of the fragments derived from human fibrinogen alpha chain; wherein the fibrinogen alpha chain fragments are flanked by flexible loops with various lengths from 1 to 100 amino acid residues; wherein the flexible loops are rich in glycine (G) and serine (S), the flexible loops may also contain glutamate (E), alanine (A), proline (P) and threonine (T), the flexible loops have greater than 95% unstructured random coil formation as determined by GOR algorithm;
(c) is rich in glycine (G), serine (S) and glutamate (E), and optionally further comprising alanine (A), proline (P), arginine (R) and threonine (T), and wherein the sum of G, S, E, A, P and T amino acid residues constitutes more than 90% of the pCloud amino acid sequence;
(d) has greater than 90% unstructured random coil formation as determined by GOR algorithm; and
(e) does not contain a T-cell epitope as predicted by TEPITOPE algorithm;
wherein the pCloud sequence can be at either or both of the N-terminal and the C-terminal end of the therapeutic polypeptide, and the pCloud sequences can optionally be placed at either or both of the N-terminal and the C-terminal end of the scaffold protein; and
wherein the pCloud polypeptides can be identical or different to each other;
wherein the fusion protein is configured, from N-terminus to C-terminus, using the following formula:
(pCloud)m-TP-(pCloud)n-Scaffold-(pCloud)k, or
(pCloud)m-Scaffold-(pCloud)n-TP-(pCloud)k
wherein m is either 0 or 1, n is either 0 or 1, k is either 0 or 1, and m+n+k>=1, the digits indicate the number of presence of the designated polypeptides;
wherein m is either 0 or 1, n is either 0 or 1, k is either 0 or 1, and m+n+k>=1, the digits indicate the number of presence of the designated polypeptides; and
wherein the fusion protein exhibits an improved pharmacokinetic profile when administered to a subject compared with the TP by itself.
US Pat. No. 10,247,271

SINTERED FRICTION MATERIAL FOR A FRICTION LINING

HOERBIGER ANTRIEBSTECHNIK...

1. A sintered friction material comprising a metallic matrix and granular constituents embedded in the matrix, the metallic matrix comprising a copper base alloy, wherein the granular constituents comprise at least a sintered cemented carbide in a proportion of 0.2 to 9 weight percent, based on the total weight of the friction material, and wherein the sintered friction material is obtained by sintering a powder blend having the following composition:60 to 91.8 weight percent of a copper base alloy;
0 to 25 weight percent of further metals or metal alloys;
5 to 15 weight percent of graphite;
3 to 10 weight percent of granular constituents, except sintered cemented carbides, selected from metal oxides, carbides, nitrides, and borides;
0.2 to 9 weight percent of a sintered cemented carbide powder; and
0 to 15 weight percent of further additives selected from adhesion promotors, solders and fluxes;
all powder constituents together being 100 weight percent.
US Pat. No. 10,248,039

CARRIER, ELECTROPHOTOGRAPHIC DEVELOPER, AND METHOD OF MANUFACTURING CARRIER

POWDERTECH CO., LTD., Ch...

1. A carrier which is a core material composed of a magnetic component and a non-magnetic component coated with a resin, characterized in thatthe carrier has water content of 200 ppm or less and cyclic siloxane content of 100 ppb or less.
US Pat. No. 10,244,712

SOYBEAN CULTIVAR S170022

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170022, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124448.
US Pat. No. 10,245,224

TOPICALLY APPLIED COSMETIC REDUCTIVE COMPOSITION CONTAINING KERATIN AND SULPHUR

Patricio Alfredo Rodrigue...

1. A topical, reductive cosmetic composition, comprising up to 15% by weight of hydrolyzed keratin and micrometer-sized Sulphur, and a remainder of the composition comprising water, compatibilizers, surfactants, thickeners, preservatives and/or flavoring agents.
US Pat. No. 10,246,504

ENGINEERED RECEPTOR AND THEIR USE

1. A chloride channel receptor, comprising:a) a transmembrane domain of a mammalian glycine receptor in the absence of the extracellular and intracellular domains of the mammalian glycine receptor, wherein the transmembrane domain comprises domains transmembrane (TM) 1, TM2, and TM3, wherein the transmembrane domain comprises a mutation at S16? of the TM2; and
b) an extracellular domain of a pH-gated pentameric ligand-gated ion channel from Gloeobacter violaceus (GLIC); and
c) interfacial sequences between the extracellular domain and transmembrane domain, wherein the interfacial sequences comprise, in N-terminal to C-terminal order, loop 2, loop 7, loop 9, pre-TM1 linker, TM2-TM3 linker, and C-terminus, wherein the interfacial sequences and C-terminus are from Gloeobacter violaceus or a human;
and wherein opening of the chloride channel receptor is induced by pH.
US Pat. No. 10,246,760

PLATINUM RECOVERY METHODS

GENERAL ELECTRIC COMPANY,...

1. A method for recovery of platinum from a coating on a component, wherein the coating comprises platinum aluminide, the method comprising:contacting the coating on the component with a reagent solution, the reagent solution comprising hexafluorosilicic acid, whereby a platinum-rich residue is formed on the component;
separating the platinum-rich residue from the component; and
collecting the platinum-rich residue.
US Pat. No. 10,244,713

SOYBEAN CULTIVAR S170017

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170017, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124447.
US Pat. No. 10,246,505

CHIMERIC ANTIGEN RECEPTORS TO CONTROL HIV INFECTION

The United States of Amer...

1. A multispecific chimeric antigen receptor protein, comprising:an N-terminal extracellular targeting segment comprising:
a first targeting domain comprising a CD4 domain that binds to HIV Env, wherein the CD4 domain comprises the D1 and D2 extracellular domains of CD4 comprising amino acids 1-208 of SEQ ID NO: 53; and
a second targeting domain comprising a carbohydrate recognition domain (CRD) from a human C-type lectin that binds to HIV Env, wherein the CRD is selected from the group consisting of a CRD from mannose-binding lectin 2 (MBL2) comprising amino acids 214-330 of SEQ ID NO: 53 and a CRD from Langerin comprising amino acids 214-354 of SEQ ID NO: 51;
wherein the first and second targeting domains bind to different sites on HIV Env, and wherein the multispecific chimeric antigen receptor protein binds to HIV Env.
US Pat. No. 10,244,714

LETTUCE LINE SVLN7347

Seminis Vegetable Seeds, ...

1. A seed of lettuce line SVLN7347, a sample of seed of said line having been deposited under ATCC Accession Number PTA-123429.
US Pat. No. 10,245,226

METHOD FOR PREVENTING NASOLACRIMAL DUCT OBSTRUCTION

KEM PATENT HOLDINGS, LLC,...

1. A method for reducing formation of fibrosis in at least one nasolacrimal duct of a patient that may occur upon the patient receiving radioactive iodine, the method comprising administering to the patient a therapeutically effective amount of perchlorate anion, wherein the administering is topically administering perchlorate anion to at least one eye of the patient, or instilling the perchlorate anion directly into the at least one nasolacrimal duct or at least one lacrimal sac of the patient.
US Pat. No. 10,246,506

METHODS FOR REDUCING LEVELS OF PROTEIN-CONTAMINANT COMPLEXES AND AGGREGATES IN PROTEIN PREPARATIONS BY TREATMENT WITH ELECTROPOSITIVE ORGANIC ADDITIVES

AGENCY FOR SCIENCE, TECHN...

1. A method of reducing the aggregate content of a sample, wherein the sample comprises a target antibody and aggregates comprising nucleic acid contaminants associated with the target antibody, the method comprising:(a) contacting the sample with an electropositive organic additive at a non-zero amount of 0.1% weight/volume or less, and an undissolved allantoin, thereby forming a mixture comprising allantoin and precipitated nucleic acid contaminants, wherein allantoin is supersaturated in the mixture and the electropositive organic additive comprises ethacridine or polyethyleneimine; and
(b) removing the undissolved allantoin and precipitated nucleic acid contaminants from the sample,
wherein the sample, after (b) comprises the target antibody and a reduced amount of the aggregates, wherein the sample is derived from a cell culture or cell culture supernatant, and the target antibody is a recombinant antibody.
US Pat. No. 10,244,715

SPINACH HYBRID SVVC8155 AND PARENTS THEREOF

SEMINIS VEGETABLE SEEDS, ...

1. A spinach seed comprising at least a first set of the chromosomes of spinach line SSBS012-1181F, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124049.
US Pat. No. 10,245,227

SOFT, CHEWABLE AND ORALLY DISSOLVABLE AND/OR DISINTEGRABLE PRODUCTS

Philip Morris USA Inc., ...

1. A method of making a pre-portioned, soft, chewable and orally-dissolvable and/or -disintegrable product comprising:dissolving a biopolymer and a sugar in water to form a solution;
adding an amount of a botanical powder to the solution;
stirring the solution to form a suspension;
gelling the suspension to form a gel;
drying the gel to form a dried gel; and
portioning the dried gel to form a pre-portioned, soft, chewable and orally-dissolvable and/or -disintegrable product, wherein
the amount of the botanical powder is distributed in a biopolymer-sugar based matrix.
US Pat. No. 10,246,507

POLYPEPTIDE, ANTI-VEGF ANTIBODY, AND ANTI-C-MET/ANTI-VEGF BISPECIFIC ANTIBODIES COMPRISING THE SAME

SAMSUNG ELECTRONICS CO., ...

1. An anti-VEGF antibody or an antigen-binding fragment thereof comprisinga CDR-H1 comprising the amino acid sequence of SEQ ID NO: 110, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 137, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 145, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 151.
US Pat. No. 10,244,716

CANOLA HYBRID CULTIVAR CL3701975H

Agrigenetics, Inc., Indi...

1. A seed of canola designated CL3701975H, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-123165.
US Pat. No. 10,246,508

ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES

CHEMOMAB LTD., Tel Aviv ...

1. A nucleic acid molecule encoding a humanized antibody that binds to at least two CCR3-binding chemokines wherein said nucleic acid molecule comprises the sequence denoted by SEQ ID NO: 1 and SEQ ID NO: 2.
US Pat. No. 10,244,717

MAIZE INBRED PH42YV

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42YV, representative seed of the variety having been deposited under ATCC accession number PTA-124767.
US Pat. No. 10,245,229

PULMONARY DELIVERY OF MRNA TO NON-LUNG TARGET CELLS

Translate Bio, Inc., Lex...

1. A method of delivery of messenger RNA (mRNA) to a non-lung cell or tissue comprising administering to the lung by nebulization a composition comprising mRNA encoding a protein and a lipid carrier vehicle comprising one or more PEG-modified lipids, wherein the administering to the lung results in the delivery of the mRNA to a non-lung cell or tissue, and wherein the protein encoded by the mRNA is detectable in the non-lung cell or tissue for at least 6 hours following the administration to the lung.
US Pat. No. 10,246,509

RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE

Regeneron Pharmaceuticals...

1. A rat or a mouse whose germline genome comprises:a restricted immunoglobulin heavy chain locus characterized by the presence of a single human unrearranged VH1-69 gene segment, one or more human unrearranged DH gene segments, and one or more human unrearranged JH gene segments operably linked to a non-human immunoglobulin heavy chain constant region nucleic acid sequence comprising at least a non-human IgM gene at an endogenous heavy chain locus of the rat or mouse,
wherein the restricted immunoglobulin heavy chain locus is capable of rearranging and forming a plurality of distinct rearrangements, wherein each rearrangement is derived from the single human VH1-69 gene segment, one of the human DH segments, and one of the human JH segments, and wherein each rearrangement encodes a different heavy chain variable domain, and
wherein the rat or mouse further comprises a population of mature IgMintIgDhi B cells in its spleen, each B cell comprising a distinct rearranged human heavy chain variable region gene sequence derived from the restricted immunoglobulin heavy chain locus.
US Pat. No. 10,246,765

MARTENSITIC CR-CONTAINING STEEL AND OIL COUNTRY TUBULAR GOODS

1. A martensitic Cr-containing steel, comprising:a chemical composition consisting of, by mass %,
Si: 0.05 to 1.00%,
Mn: 0.1 to 1.0%,
Cr: 8 to 12%,
V: 0.01 to 1.0%,
sol. Al: 0.005 to 0.10%,
N: not more than 0.100%,
Nb: 0 to 1%,
Ti: 0 to 1%,
Zr: 0 to 1%,
B: 0 to 0.01%,
Ca: 0 to 0.01%,
Mg: 0 to 0.01%, and
rare earth metal (REM): 0 to 0.50%, and further consisting of one or two selected from the group consisting of
Mo: 0 to 2% and
W: 0 to 4%, with the balance being Fe and impurities, wherein the impurities include
C: not more than 0.10%,
P: not more than 0.03%,
S: not more than 0.01%,
Ni: not more than 0.5%, and
O: not more than 0.01%, and wherein
an effective Cr amount defined by Formula (1) is not less than 8%, and
an Mo equivalent defined by Formula (2) is 0.03 to 2%;
a micro-structure wherein a grain size number (ASTM E112) of prior-austenite crystal grain is not less than 8.0, and which consists of, in volume fraction, 0 to 5% of ferrite and 0 to 5% of austenite, with the balance being tempered martensite; and
a yield strength of 379 to less than 551 MPa, wherein
a grain-boundary segregation ratio, which is defined, when either one of Mo and W is contained, as a ratio of a maximum content at grain boundaries to an average content within grains of the contained element, and when Mo and W are contained, as an average of ratios of a maximum content at grain boundaries to an average content within grains of each element, is not less than 1.5:
Effective Cr amount=Cr?16.6×C  (1)
Mo equivalent=Mo+0.5×W  (2)
where, symbols of elements in Formulae (1) and (2) are substituted by corresponding contents (by mass %) of the elements.
US Pat. No. 10,244,718

MAIZE INBRED PH2FNV

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2FNV, representative seed of the variety having been deposited under ATCC accession number PTA-125259.
US Pat. No. 10,245,230

METHOD FOR INCORPORATING ACTIVE AGENTS INTO A HYDROPHILIC POLYMER FOAM

LABORATOIRES URGO, Cheno...

1. A process for manufacturing a hydrophilic polymer foam exhibiting a gradient of a water-soluble active agent, the process comprising:a) depositing an aqueous solution or dispersion comprising the water-soluble active agent on an impermeable nonporous support;
b) pouring a precursor mixture of the foam, in a form of an aqueous dispersion comprising either monomers or prepolymers, over the aqueous solution or dispersion that has been deposited on the support at the end of step a), wherein the aqueous solution or dispersion that has been deposited on the support at the end of step a) dissolves in the precursor mixture of the foam;
c) polymerizing the precursor mixture in which the water-soluble active agent is dissolved in step b) to produce the hydrophilic polymer foam incorporating the water-soluble active agent;
d) drying the hydrophilic polymer foam; and
e) separating the impermeable nonporous support from the foam after the foam has been dried in step d),
wherein 80% -90% of the total weight of the water-soluble active agent is found in the lower 33% of the total volume of the hydrophilic polymer foam, which is the volume of the foam closest to the impermeable nonporous support at the end of step d).
US Pat. No. 10,246,510

KIR3DL2 BINDING AGENTS

INNATE PHARMA, Marseille...

1. An isolated monoclonal antibody selected from the group consisting of:(a) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 4 (HCDR1), SEQ ID NO: 7 (HCDR2) and SEQ ID NO: 9 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 10, 11 and 12, respectively;
(b) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 15 (HCDR1), SEQ ID NO: 18 (HCDR2) and SEQ ID NO: 20 (HCDR3) respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 21, 22 and 23, respectively;
(c) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 16 (HCDR1), SEQ ID NO: 18 (HCDR2) and SEQ ID NO: 28 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 29, 30 and 31, respectively;
(d) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 26 (HCDR1), SEQ ID NO: 36 (HCDR2) and SEQ ID NO: 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 39, 40 and 41, respectively;
(e) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 16 (HCDR1), SEQ ID NO: 36 (HCDR2) and SEQ ID NO: 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 44, 45 and 41, respectively; and
(f) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 48 (HCDR1), SEQ ID NO: 51 (HCDR2) and SEQ ID NO: 53 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 54, 55 and 56, respectively.
US Pat. No. 10,246,766

CONCURRENT FLOW OF ACTIVATING GAS IN LOW TEMPERATURE CARBURIZATION

SWAGELOK COMPANY, Solon,...

1. A process for surface hardening a workpiece made from an iron, nickel and/or chromium based alloy by gas carburization in which an unsaturated hydrocarbon is contacted with the workpiece inside a carburization reactor under a pressure of about 3.5 to 100 torr and at an elevated carburization temperature to cause carbon to diffuse into the workpiece surfaces thereby forming a hardened primary surface layer which is essentially free of carbide precipitates as well as a thermal oxide film, the process further comprising increasing the rate at which carburization occurs by feeding a carbon-free, halogen-containing activating compound to the carburization reactor simultaneously with feeding the unsaturated hydrocarbon to the carburization reactor, wherein the unsaturated hydrocarbon is acetylene, the concentration of the of the unsaturated hydrocarbon inside the carburization reactor is about 8 to 35 vol. % and the concentration of the carbon-free, halogen-containing activating compound inside the carburization reactor is about 0.5 to 3 vol. %.
US Pat. No. 10,244,719

SOYBEAN VARIETY 38G14B4189

Agrigenetics, Inc., Indi...

1. A seed of soybean variety 38G14B4189, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-125136.
US Pat. No. 10,245,231

DRY ACID CONCENTRATE IN GRANULATE FORM

Fresenius Medical Care De...

1. A dry concentrate suitable to form a liquid acid concentrate or a part of a liquid acid concentrate usable in dialysis comprisinga first component comprising a first granulate comprising a plurality of first granules comprising sodium chloride and glucose, wherein the first granules are aggregates comprising sodium chloride and glucose and
a second component comprising a second granulate comprising a plurality of second granules, wherein said second granules comprise at least one further physiologically acceptable electrolyte, which is different from sodium chloride,
or a second component in the form of a powder, wherein said powder comprises at least one further physiologically acceptable electrolyte which is different from sodium chloride, and
wherein said powder comprises a plurality of fine particles, wherein each particle comprises or consists of one of said at least one further physiologically acceptable electrolyte,
or a mixture of said second granulate and said powder;
wherein said concentrate is substantially free of a base component that is suitably used in dialysis, and the second component comprises MgCl2, CaCl2 and KCl.
US Pat. No. 10,246,511

FUSION POLYPEPTIDE CAPABLE OF BINDING SIMULTANEOUSLY TO VEGF-C AND VEGF-D

SAMSUNG ELECTRONICS CO., ...

1. A fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D, comprising a VEGFR2 extracellular domain, a VEGFR3 extracellular domain, and the Fc region of an immunoglobulin, wherein the VEGFR2 extracellular domain comprises Ig-like domain 2, and the VEGFR3 extracellular domain comprises Ig-like domain 2.
US Pat. No. 10,244,720

SOYBEAN VARIETY SPESH71

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PESH71, representative seed of the variety having been deposited under ATCC Accession Number PTA-125283.
US Pat. No. 10,245,232

CRYSTALLINE MICROSPHERES AND THE PROCESS OF MANUFACTURING THE SAME

SPI PHARMA, INC., Wilmin...

1. A microsphere comprising a core material, wherein the microsphere has a circularity greater than 0.95 and an aspect ratio of shortest diameter to longest diameter that is greater than 0.95, wherein the microsphere has a skeletal density from about 1.4595 g/cc to about 1.4651 g/cc, and wherein the microsphere has a moisture gain of less than 1.0% at 90% relative humidity.
US Pat. No. 10,246,512

IL-2R BETA/COMMON GAMMA CHAIN ANTIBODIES

Agency for Science, Techn...


US Pat. No. 10,244,721

SOYBEAN VARIETY 5PQNE01

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PQNE01, representative seed of the variety having been deposited under ATCC Accession Number PTA-125284.
US Pat. No. 10,246,513

ANTIBODIES, COMPOUNDS AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF MALE INFERTILITY

1. A method of increasing sperm production in a male subject, comprising:selecting a male subject with spermatogenic failure; and
administering to said male subject a therapeutically effective amount of a composition comprising Denosumab or an antigen binding domain thereof, or osteoprotegerin (OPG).
US Pat. No. 10,244,722

PLANTS AND SEEDS OF CORN VARIETY CV754236

MONSANTO TECHNOLOGY LLC, ...

1. A plant of corn variety CV754236, wherein representative seeds of corn variety CV754236 have been deposited under ATCC Accession No. PTA-124508.
US Pat. No. 10,246,514

SINGLE DOMAIN ANTIBODIES THAT BIND TO HUMAN CD20

The United States of Amer...

1. An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 6.
US Pat. No. 10,244,723

SOYBEAN VARIETY 01068058

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01068058, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124886.
US Pat. No. 10,245,235

COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS

The Charlotte-Mecklenburg...

1. A method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, comprising administering a therapeutically effective amount of a ribitol to a subject in need thereof daily for at least 30 days, thereby treating the disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, wherein the disorder associated with a mutation or loss of function in the FKRP gene is selected from the group consisting of limb-girdle muscular dystrophy (LGMD), Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), congenital muscular dystrophy (CMD), and any combination thereof.
US Pat. No. 10,246,515

METHODS OF TREATING HEDGEHOG-RELATED DISEASES WITH AN ANTI-LGR5 ANTIBODY

Genentech, Inc., South S...

1. A method of treating a hedgehog-related disease in an individual comprising administering to the individual an effective amount of an anti-Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 (LGR5) antibody, wherein the anti-LGR5 antibody comprises:a) hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29;
b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and HVR-L3; comprising the amino acid sequence of SEQ ID NO: 59;
c) a heavy chain variable domain (VH) sequence of SEQ ID NO: 6 and a light chain variable domain (VL) sequence of SEQ ID NO: 5;
d) a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7;
e) a VH sequence of SEQ ID NO: 10 and a VL sequence of SEQ ID NO: 9;
f) a VH sequence of SEQ ID NO: 12 and a VL sequence of SEQ ID NO: 11;
g) a VH sequence of SEQ ID NO: 14 and a VL sequence of SEQ ID NO: 13;
h) a VH sequence of SEQ ID NO: 16 and a VL sequence of SEQ ID NO: 15;
i) a VH sequence of SEQ ID NO: 18 and a VL sequence of SEQ ID NO: 17;
j) a VH sequence of SEQ ID NO: 20 and a VL sequence of SEQ ID NO: 19; or
k) a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
US Pat. No. 10,244,724

SOYBEAN VARIETY 01064667

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01064667, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124966.
US Pat. No. 10,245,236

METHOD AND PRODUCT FOR TREATING MOUTH-RELATED DISORDERS

1. A treatment product for a mouth-related disorder, comprising:an initially sealed dispensing package, and
a composition disposed in said package, the composition comprising one or more vitamins, one or more amino acids, and Xylitol,
wherein the composition is a liquid at room temperature and solid or substantially solid when first intended to be administered to a subject's mouth,
wherein the one or more vitamins includes vitamin C in the form of ESTER-C vitamin C formula and vitamin B6 in the form of Pyridoxine HCL USP, and
wherein the one or more amino acids includes L-Lysine HCL and L-Glutamine.
US Pat. No. 10,246,516

ANTI-LA ANTIBODIES AND THEIR USE FOR IMMUNOTARGETING

GEMoaB Monoclonals GmbH, ...

and(b) a binding unit comprising:
a second antibody which binds specifically to an effector cell or
a ligand which binds specifically to an effector cell.
US Pat. No. 10,244,725

MAIZE INBRED PH42KS

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42KS, representative seed of the variety having been deposited under ATCC accession number PTA-124768.
US Pat. No. 10,245,237

COMPRESSED TABLET CONTAINING CANNABIDIOL, METHOD FOR ITS MANUFACTURE AND USE OF SUCH TABLET IN ORAL TREATMENT OF PSYCHOSIS OR ANXIETY DISORDERS

Echo Pharmaceuticals B.V....

1. A compressed tablet having a tablet weight of 60-1200 mg and comprising:(a) 50-95 wt. % of a granulate;
(b) 5-50 wt. % of lactose; and
(c) 0-30 wt. % of other tablet excipients;
wherein the granulate comprises:
(i) 2-15 wt. % of cannabidiol;
(ii) 2-30 wt. % of sucrose fatty acid mono-ester;
(iii) 30-96 wt. % of lactose; and
(iv) 0-25 wt. % of other granulate excipients,
wherein the granulate is composed of granules comprising lactose particles that are held together by a solid dispersion comprising cannabidiol and sucrose fatty acid mono-ester and optionally other granulate excipients; and
wherein the compressed tablet is obtained by:
(a) providing a lactose powder;
(b) combining the lactose powder with a granulation fluid comprising a solution of cannabidiol, sucrose fatty acid mono-ester and optionally other granulate excipients in an organic solvent;
(c) removing the organic solvent by evaporation to produce a granulate;
(d) mixing the granulate with lactose and optionally other tablet excipients to produce a tablet mixture; and
(e) compressing the tablet mixture into a tablet.
US Pat. No. 10,246,517

ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOF

APROGEN KIC INC., Seongn...

1. An antibody or an antigen-binding fragment thereof, binding to carbonic anhydrase, wherein the antibody or antigen-binding fragment thereof comprises a CDR-H1 comprising SEQ ID NO: 14; a CDR-H2 comprising SEQ ID NO: 15; a CDR-H3 comprising SEQ ID NO: 16; a CDR-L1 comprising SEQ ID NO: 17; a CDR-L2 comprising SEQ ID NO: 18; and a CDR-L3 comprising SEQ ID NO: 19.
US Pat. No. 10,246,773

METHOD FOR FORMING AMORPHOUS THIN FILM

EUGENE TECHNOLOGY CO., LT...

1. A method for forming an amorphous thin film, the method comprising:forming a seed layer on a surface of a base by supplying aminosilane-based gas on the base; and
forming the amorphous thin film having a predetermined thickness on the seed layer,
wherein said forming the amorphous thin film comprises:
forming a first boron-doped amorphous thin film having a first thickness on the seed layer; and
forming a second boron-doped amorphous thin film having a second thickness on the first boron-doped amorphous thin film, and
wherein a first source gas used in said forming the first boron-doped amorphous thin film includes boron-based gas and silane-based gas and be supplied to the seed layer, and a second source gas used in said forming the second boron-doped amorphous thin film includes the boron-based gas, the second source gas being different from the first source gas and being supplied to the first boron-doped amorphous thin film.
US Pat. No. 10,244,726

PEA VARIETY SV6844QG

SEMINIS VEGETABLE SEEDS, ...

1. A seed of pea line SV6844QG, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124090.
US Pat. No. 10,245,238

COMPOSITION FOR ORAL INTAKE

THERAVALUES CORPORATION, ...

1. A method for producing a complex of (A) curcumin and/or an analog thereof and (B) a water-soluble cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and a mixture thereof, wherein a weight ratio (A/B) is in a range of 0.02 to 10, the method comprising:dissolving the curcumin and/or the analog thereof and the water-soluble cellulose derivative in a water-organic solvent mixed solvent, to obtain a solution; and
removing water and the organic solvent from the solution.
US Pat. No. 10,246,518

NUCLEIC ACIDS ENCODING BISPECIFIC ANTIBODIES BINDING TO BETA-KLOTHO AND FIBROBLAST GROWTH FACTOR RECEPTOR 1

Genentech, Inc., South S...

1. A nucleic acid encoding a bispecific antibody, or an antigen-binding portion thereof, that binds to beta-Klotho (KLB) and Fibroblast Growth Factor Receptor 1c (FGFR1c), wherein the bispecific antibody, or an antigen-binding portion thereof, comprises:(i) a first arm comprising (a) a heavy chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 136; (b) a heavy chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 137; (c) a heavy chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 138; (d) a light chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 139; (e) a light chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 140; and (f) a light chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 141; and
(ii) a second arm comprising (a) a heavy chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 15; (b) a heavy chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 31; (c) a heavy chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 47; (d) a light chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 62; (e) a light chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 78; and (f) a light chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 93.
US Pat. No. 10,244,727

PEA VARIETY SV1231QF

SEMINIS VEGETABLE SEEDS, ...

1. A seed of pea line SV1231QF, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124091.
US Pat. No. 10,245,239

ASTAXANTHIN ANTI-INFLAMMATORY SYNERGISTIC COMBINATIONS

LYCORED LTD., Beer Sheva...

1. A composition comprising: lycopene, astaxanthin and carnosic acid, wherein the molar concentration ratio of astaxanthin to carnosic acid is from 1:1 to 1:10.
US Pat. No. 10,246,519

NSP4 INHIBITORS AND METHODS OF USE

Genentech, Inc., South S...

1. An isolated nucleic acid encoding an anti-NSP4 antibody comprising a heavy chain and a light chain, wherein the light chain comprises an HVR-L1 comprising the sequence of SEQ ID NO:19, an HVR-L2 comprising the sequence of SEQ ID NO:11, and an HVR-L3 comprising the sequence of SEQ ID NO:12; and wherein the heavy chain comprisesan HVR-H1 comprising the sequence of SEQ ID NO:56, an HVR-H2 comprising the sequence of SEQ ID NO:57, and an HVR-H3 comprising the sequence of SEQ ID NO:58.
US Pat. No. 10,244,728

PEPPER HYBRID SV0198PB AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A pepper seed comprising at least a first set of the chromosomes of pepper line SBR-E712439 or pepper line SBR-E711416, a sample of seed of said lines having been deposited under ATCC Accession Number PTA-124022 and ATCC Accession Number PTA-124021, respectively.
US Pat. No. 10,246,520

ANTIBODY AGAINST ALOPECIA-INDUCING SUBSTANCE AS ANTIGEN, COMPOSITION AND PRODUCTION METHOD

OSTRICH PHARMA KK, Kyoto...

1. A haircare product comprising an ostrich antibody against a hair loss-inducing substance as an antigen, wherein the hair loss-inducing substance is an enzyme or hormone which is the cause of alopecia, and wherein the hair loss-inducing substance comprises 5?-reductase, dihydrotestosterone, or 5?-reductase and dihydrotestosterone.
US Pat. No. 10,245,241

NASAL IRRIGATION

1. A process for producing and protecting a hygroscopic mixture powder comprising xylitol for use in nasal irrigation, the process comprising:blending chemical compounds that formulate lactated ringers in a blender to create a uniform mixture, wherein the chemical compounds comprise sodium chloride, sodium lactate powder, potassium chloride, calcium chloride, and xylitol;
grinding the uniform mixture comprising sodium chloride, sodium lactate, powder, potassium chloride, calcium chloride, and xylitol;
blending the grinded uniform mixture comprising sodium chloride, sodium lactate powder, potassium chloride, calcium chloride, and xylitol;
sieving the blended mixture to reduce the blended mixture into the hygroscopic mixture of the lactated ringers with xylitol, for use in nasal irrigation; and
protecting the hygroscopic mixture from moisture and air by inserting the hygroscopic mixture in a sealed package to protect the hygroscopic mixture from moisture and air,
wherein the blending of the chemical compounds comprise 60.50% wt. of sodium chloride, 32.30% wt. of sodium lactate powder, 3.12% wt. of potassium chloride, 2.08% wt. of calcium chloride, and 2.00% wt. of xylitol.
US Pat. No. 10,246,521

COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF

Boehringer Ingelheim Inte...

1. A compound comprising a first polypeptide and a second polypeptide, wherein:(A) said first polypeptide comprises:
(i) a light chain variable domain of a first immunoglobulin (VL1) specific for a first target protein;
(ii) a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second target protein; and
(iii) a hinge region, a heavy chain constant region 2 (CH2) and a heavy chain constant region 3 (CH3); and
(B) said second polypeptide comprises:
(i) a light chain variable domain of the second immunoglobulin (VL2) specific for said second target protein;
(ii) a heavy chain variable domain of the first immunoglobulin (VH1) specific for said first target protein;
wherein:
a) said VL1 and VH1 associate to form a binding site that binds said first target protein;
b) said VL2 and VH2 associate to form a binding site that binds said second target protein;
c) said heavy chain constant region 2 (CH2) comprises a tyrosine at position 252, a threonine at position 254 and a glutamic acid a position 256, numbered according to the EU index as in Kabat for the CH2 of a conventional antibody; and
d) said first target protein is B-cell activating factor (“BAFF”) and said second target protein is Interleukin-23A (“IL-23A”) or said first target protein is IL-23A and said second target protein is BAFF,
and wherein:
(i) said VL1 comprises the amino acid sequence of SEQ ID NO:2, said VH1 comprises the amino acid sequence of SEQ ID NO:1, said VL2 comprises the amino acid sequence of SEQ ID NO:4 and said VH2 comprises the amino acid sequence of SEQ ID NO:3; or
(ii) said VL1 comprises the amino acid sequence of SEQ ID NO:4, said VH1 comprises the amino acid sequence of SEQ ID NO:3, said VL2 comprises the amino acid sequence of SEQ ID NO:2 and said VH2 comprises the amino acid sequence of SEQ ID NO:1; or
(iii) said VL1 comprises the amino acid sequence of SEQ ID NO:89, said VH1 comprises the amino acid sequence of SEQ ID NO:88, said VL2 comprises the amino acid sequence of SEQ ID NO:4 and said VH2 comprises the amino acid sequence of SEQ ID NO:3; or
(iv) said VL1 comprises the amino acid sequence of SEQ ID NO:4, said VH1 comprises the amino acid sequence of SEQ ID NO:3, said VL2 comprises the amino acid sequence of SEQ ID NO:89 and said VH2 comprises the amino acid sequence of SEQ ID NO:88; or
(v) said VL1 comprises the amino acid sequence of SEQ ID NO:91, said VH1 comprises the amino acid sequence of SEQ ID NO:90, said VL2 comprises the amino acid sequence of SEQ ID NO:4 and said VH2 comprises the amino acid sequence of SEQ ID NO:3; or
(vi) said VL1 comprises the amino acid sequence of SEQ ID NO:4, said VH1 comprises the amino acid sequence of SEQ ID NO:3, said VL2 comprises the amino acid sequence of SEQ ID NO:91 and said VH2 comprises the amino acid sequence of SEQ ID NO:90.
US Pat. No. 10,245,242

NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND COMPOSITIONS ENRICHED WITH THE R-ENANTIOMER AND METHODS OF USE

AXCESS GLOBAL SCIENCES, L...

1. A composition for increasing ketone body level in a subject, comprising:a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate,
wherein the non-racemic mixture contains from 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and 45% to 2% by enantiomeric equivalents of the S-beta-hydroxybutyrate,
wherein the non-racemic mixture comprises one or more salts of R-beta-hydroxybutyrate.
US Pat. No. 10,246,778

ELECTROLESS NICKEL PLATING SOLUTION AND METHOD

MacDermid Acumen, Inc., ...

17. A process of plating a substrate to provide a bright electroless nickel deposit thereon, the method comprising the steps of:a) preparing a substrate to accept electroless nickel plating thereon; and
b) plating the substrate with an electroless nickel plating solution, the electroless nickel plating solution comprising;
1) a source of nickel ions;
2) a reducing agent;
3) one or more complexing agents, the one or more complexing agents in a concentration of about 15 to about 75 g/L;
4) one or more bath stabilizers, the one or more bath stabilizers comprising a source of bismuth ions;
5) a brightener selected from the group consisting of alkyl or aryl substituted sulfonamides, alkyl or aryl substituted sulfonic acids, alkyl or aryl substituted sulfosuccinates, and alkyl or aryl substituted sulfonates, the sulfonated compound in a concentration of about 0.1-3.0 mg/L; and
6) 2-aminothiazole;wherein the deposited electroless nickel layer has a measured gloss unit value above about 170.
US Pat. No. 10,245,243

NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND COMPOSITIONS ENRICHED WITH THE S-ENANTIOMER AND METHODS OF USE

AXCESS GLOBAL SCIENCES, L...

1. A composition for administering ketone bodies and ketone body precursors to a subject, comprising:a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate,
wherein the non-racemic mixture comprises from 52% to 85% by enantiomeric equivalents of the S-beta-hydroxybutyrate and 48% to 15% by enantiomeric equivalents of the R-beta-hydroxybutyrate.
US Pat. No. 10,246,523

FLUORESCENT STARCH NANOCRYSTAL AND PREPARATION METHOD AND APPLICATION THEREOF

Jiangnan University, Wux...

1. A method for preparing a fluorescent starch nanocrystal, the method comprising:(1) an activating step consisting of adding 1 w/v % to 8 w/v % of starch nanocrystal to an alkaline solution having a pH of 8.0 to 11.0 and continuously stirring for 2 to 6 h to obtain an alkali-activated starch nanocrystal, and optionally separating and washing the alkali-activated starch nanocrystal with a mixed solution of ethanol and water;
(2) adding 0.1 w/v % to 0.8 w/v % of benzoyl peroxide to a mixed solution of ethanol and water and continuously stirring at 100 to 400 rpm at room temperature until benzoyl peroxide is fully dissolved to form a benzoyl peroxide solution, then adding 1 v/v % to 5 v/v % ?-aminopropyl triethoxysilane to the benzoyl peroxide solution to carry out hydrolysis for 0.5 to 6 h to form a silane hydrolysate solution;
(3) adding the activated starch nanocrystal of step (1) to the silane hydrolysate solution of step (2) and continuously stirring for 2 to 6 h followed by rotary evaporation and drying to obtain amino silane modified starch nanocrystal; and
(4) adding 0.1 w/v % to 2.0 w/v % of the amino silane modified starch nanocrystal obtained from step (3) to a mixed solution of methanol and water containing 0.1 w/v % to 1.5 w/v % fluorescein isothiocyanate and keeping in dark place at room temperature for 12 to 36 h to obtain the fluorescent starch nanocrystal.
US Pat. No. 10,245,244

PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

HEART BIOTECH PHARMA LIMI...

1. A pharmaceutical formulation comprising polymeric nanoparticles encapsulated within crosslinked polymeric microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of pulmonary arterial hypertension (PAH) loaded within them, wherein the therapeutic agent is selected from the group consisting of a prostacyclin synthetic analog, PPAR ? agonist, and NO donor, wherein the polymeric nanoparticles comprise a chitosan-derivative polymer selected from the group consisting of chitosan-PEG-Cholanic acid, chitosan-PEG-Stearic acid, and chitosan-PEG-Oleic acid, and wherein the PEG component of the polymer is connected to the chitosan component of the polymer by an ester bond, and wherein both the PEG component and the fatty acid component are connected to the same monosaccharide ring of the chitosan.
US Pat. No. 10,246,524

METHOD FOR PREPARING SULFOBUTYL ETHER-?-CYCLODEXTRIN

ASYMCHEM LABORATORIES (TI...

1. A method for preparing sulfobutyl ether-?-cyclodextrin, the method consisting of specific preparation steps are as follows:Step (1): synthesis reaction: controlling the temperature at 20° C. to 30° C., adding an ether solvent and a sodium hydroxide aqueous solution having a concentration of 3.7 N into a reaction flask, increasing the temperature to 60° C. to 70° C., adding a ?-cyclodextrin into the reaction flask; dropping an 1,4-sulfobutyrolactone to the reaction solution at 70° C. to 75° C., stirring the reaction solution at 70° C. to 75° C. after the dropping, controlling the reaction solution at pH>9 by adding a second sodium hydroxide aqueous solution having a concentration of 3.7 N, reducing the temperature to 20° C. to 25° C. when the percentage of unreacted ?-cyclodextrin accounts for less than 0.5% wt of the total input of the ?-cyclodextrin as measured by High Performance Liquid Chromatography, then adjusting the reaction solution to pH=7.0 to 7.5 with a concentrated hydrochloric acid, and providing an obtained mixed reaction solution in a purification operation in the next step directly;
Step (2): purification: controlling the temperature at 20° C. to 30° C., adding the mixed reaction solution obtained in Step (1) into a dialysis bag, performing ultrasonic dialysis until the content of chloride ions is less than 10 ppm, decolorizing the dialysate by an absorbent active carbon, followed by filtrating to obtain a filtrate having ultraviolet absorption less than 0.5 AU, washing the active carbon twice by deionized water of 1 to 2 ml/g of the total input of the ?-cyclodextrin, combining wash solution with the filtrate, concentrating the combined wash solution and filtrate by a 0.65 to 0.22 ?m filter until the percentage of the sulfobutyl ether-?-cyclodextrin accounts for 30 wt % to 35 wt % of the total amount of the final solution, performing freeze-drying to obtain the sulfobutyl ether-?-cyclodextrin, and measuring an average 6.7 degree of substitution of the sulfobutyl ether group in capillary electrophoresis the amount of the ether solvent is 0.02 to 0.20 ml/g of the ?-cyclodextrin.
US Pat. No. 10,246,780

NON-COMBUSTIBLE COLOR STEEL SHEET FOR HOUSEHOLD APPLIANCES AND BUILDING MATERIALS AND METHOD FOR MANUFACTURING SAME

Hyundai Steel Company, I...

1. A method for manufacturing an incombustible color-coated steel sheet, comprising the steps of:(a) applying an under-coating agent to a base steel sheet, followed by heat drying, thereby forming a pretreatment layer;
(b) applying a primer coating composition to the pretreatment layer, followed by heat drying, thereby forming a primer layer; and
(c) applying a flame-retardant coating composition to the primer layer, followed by drying and curing at a temperature of 200° C., thereby forming a flame-retardant coating layer, the flame- retardant coating composition comprising, based on 100 parts by weight of the flame-retardant coating composition, 15-20 parts by weight of silica sol, 5-15 parts by weight of polyurethane resin, 40-70 parts by weight of a solvent, 1-3 parts by weight of an acid catalyst, 0.1-2.0 parts by weight of an acid stabilizer, and 5-20 parts by weight of a pigment,
wherein the flame-retardant coating layer has a thickness of 5 to 10 ?m.
US Pat. No. 10,245,245

COMPOSITIONS AND METHODS FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATION

Vireo Systems, Inc., Mad...

1. A method for preventing or reducing neurodegeneration in a human having the huntingtin gene mutation, comprising:administering to the human an effective amount of a composition comprising creatine hydrochloride, wherein the effective amount comprises a daily dose of creatine hydrochloride of about 2 grams to about 12 grams.
US Pat. No. 10,246,525

PROCESS FOR PRODUCING CONJUGATED DIENE POLYMER

Asahi Kasei Kabushiki Kai...

1. A process for producing a conjugated diene polymer, the process comprising:a production step of producing a conjugated diene polymer solution comprising a conjugated diene polymer and a solvent; and
a devolatilization step of heating the conjugated diene polymer solution while conveying the conjugated diene polymer solution with an apparatus comprising rotary twin screws, thereby devolatilizing the solvent,
wherein a motor current value of the screw in the devolatilization step and a motor current value of the screw under no load satisfy following relational expression (1):
1.05?((I1)/(I0))?2.00  (1)wherein I1 represents the motor current value [A] of the screw in the devolatilization step and I0 represents the motor current value [A] of the screw under no load,wherein:a ratio of a screw length to a screw diameter in the apparatus is 4.0 or more and 12 or less; and,
in the devolatilization step, an inner volume of the apparatus and an amount of the solvent volatilizing per unit time satisfy following relational expression (2):
1.0?((VA)/(V0))?50  (2)wherein (V0) represents the inner volume [L] of the apparatus and (VA) represents the amount [L] of the solvent volatilizing per unit time [h].
US Pat. No. 10,245,246

?-SUBSTITUTED ?-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS

QUADRIGA BIOSCIENCES, INC...

1. A method of treating cancer in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of (3S)-3-amino-4-[5-[bis(2-chloroethyl)amino]-2-methyl-phenyl]butanoic acid (5), or a pharmaceutically acceptable salt thereof, wherein the cancer comprises glioblastoma, triple negative breast cancer, melanoma, prostate cancer, or multiple myeloma.
US Pat. No. 10,246,527

POLYMER COMPOSITION COMPRISING A POLYOLEFIN PRODUCED IN A HIGH PRESSURE PROCESS, A HIGH PRESSURE PROCESS AND AN ARTICLE

Borealis AG, Vienna (AT)...

1. A direct current (DC) power cable comprising a conductor surrounded by at least an inner semiconductive layer, an insulation layer and an outer semiconductive layer, in that order, wherein the insulation layer comprises a polymer composition having an electric conductivity of 0.50×10?15 S/m or less, when measured according to DC conductivity method using a tape sample consisting of the polymer composition as described under “Determination Methods”, the polymer composition comprising a polyolefin which is a low density polyethylene (LDPE) copolymer of ethylene with a polyunsaturated comonomer obtained by a high pressure polymerization process comprising:(a) compressing ethylene with the polyunsaturated comonomer under pressure in a compressor, wherein a compressor lubricant is used for lubrication,
(b) polymerizing ethylene with the polyunsaturated comonomer in a polymerization zone,
(c) separating the obtained polyolefin from the unreacted products and recovering the separated polyolefin in a recovery zone,
wherein the compressor lubricant comprises a mineral oil.
US Pat. No. 10,246,528

CHROMIUM (III) CATALYST SYSTEMS WITH ACTIVATOR-SUPPORTS

Chevron Phillips Chemical...

1. An olefin polymerization process, the process comprising:(i) combining a chromium (III) compound with an activator-support comprising a solid oxide treated with an electron-withdrawing anion to form a mixture;
(ii) subjecting the mixture to a non-oxidizing atmosphere at a peak temperature to produce a supported chromium catalyst; and
(iii) contacting the supported chromium catalyst and a co-catalyst with ethylene and an optional olefin comonomer in a polymerization reactor system under polymerization conditions to produce an ethylene polymer, wherein a molar ratio of co-catalyst:chromium is in a range from about 50:1 to about 500:1; and
wherein the ethylene polymer has a melt index in a range from 0 to about 0.5 g/10 min, and a Mw in a range from about 400,000 to about 900,000 g/mol.
US Pat. No. 10,246,784

DECREASING CORROSION ON METAL SURFACES WITH APATITE FORMING COMPONENTS

Baker Hughes, a GE compan...

1. A method for decreasing corrosion to a metal surface in an oil production system, wherein the method comprises:circulating an aqueous-based fluid comprising apatite forming components into an oil production system;
contacting at least one metal surface within the oil production system with the apatite forming components; and
forming at least one apatite species selected from the group consisting of fluoroapatite, chloroapatite, and combinations thereof on the at least one metal surface with the apatite forming components;
wherein less corrosion occurs to at least one metal surface as compared to an otherwise identical method without the contact of at least one metal surface with the apatite forming components.
US Pat. No. 10,245,250

METHOD OF IMPROVING VISUAL PROCESSING, VISUAL ACUITY, OR BOTH BY ADMINISTERING COMPOSITIONS COMPRISING RRR-ALPHA-TOCOPHEROL TO INFANTS

ABBOTT LABORATORIES, Abb...

1. A method of improving the visual processing of a healthy infant, the method comprising administering a nutritional composition comprising RRR-alpha-tocopherol to the infant.
US Pat. No. 10,246,530

METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION AND A PROCESS FOR PROPYLENE POLYMERIZATION

TOHO TITANIUM CO., LTD., ...

1. A method for producing an olefin polymerization catalyst component, the method comprising:bringing a magnesium compound, a tetravalent titanium halide compound, an organic compound represented the following general formula (1)
R1k(C6H4-k)(COOR2)(COOR3)  (1) andan organic compound represented the following general formula (2)R4R5C?C(COOR6)(COOR7)  (2)into contact with each other at the same step,wherein R1 is a halogen atom or an alkyl group having 1 to 8 carbon atoms, R2 and R3 are a linear alkyl group having 1 to 6 carbon atoms, provided that R2 and R3 are either identical or different, and k is an integer from 0 to 4, provided that a plurality of R1 are either identical or different when k is an integer from 2 to 4, andwherein R4 and R5 are independently an atom or group selected from a hydrogen atom, halogen, a linear alkyl group having 1 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, a vinyl group, a linear or branched alkenyl group having 3 to 20 atoms, a cycloalkenyl group having 3 to 20 carbon atoms, an aromatic hydrocarbon group having 6 to 20 carbon atoms, provided that R4 and R5 optionally bond to each other to form a ring, and the number of carbon atoms of R5 is 2 or more when R4 is a hydrogen atom or a methyl group; andwherein R6 and R7 are independently a linear alkyl group having 1 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, a vinyl group, a linear or branched alkenyl group having 3 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, a cycloalkenyl group having 3 to 20 carbon atoms, or an aromatic hydrocarbon group having 6 to 20 atoms.
US Pat. No. 10,244,739

GENETICALLY EDITED PIGS COMPRISING A MODIFICATION IN THE RELA GENE

The University Court of t...

1. A method of producing a genetically edited pig whose genome comprises a modification heterozygous or homozygous of the RELA gene, wherein the modification produces a truncated RelA protein that lacks transactivation domain 1 and exhibits a phenotype of reduced NFkappaB signaling capacity when compared to a wild type pig, the method comprising the steps of:(a) providing a pig cell;
(b) introducing into said pig cell a site-specific nuclease that targets the endogenous pig RELA gene, wherein said introduction creates a modification of the RELA gene, wherein the modification produces a truncated RelA protein that lacks transactivation domain 1 and has reduced expression or activity; and
(c) generating a pig from said cell whose genome comprises either a heterozygous or homozygous modification of the RELA gene, wherein said pig expresses a truncated RelA protein that lacks transactivation domain 1 and exhibits a phenotype of reduced NFkappaB signaling capacity when compared to a wild type pig.
US Pat. No. 10,245,764

MODIFIED RESIN SYSTEMS SUITABLE FOR LIQUID RESIN INFUSION

Cytec Industries Inc., W...

7. A process according to claim 6, wherein the preform comprises one or more layers of fabric comprising reinforcing fibrous material.
US Pat. No. 10,246,788

ELECTROLYTIC GENERATION OF MANGANESE (III) IONS IN STRONG SULFURIC ACID USING AN IMPROVED ANODE

MacDermid Acumen, Inc., ...

1. An electrolytic cell comprising:an electrolyte solution comprising manganese(III) ions in a solution of acid;
a cathode in contact with the electrolyte solution; and
an anode in contact with the electrolyte solution, wherein the anode comprises a material selected from the group consisting of vitreous carbon, reticulated vitreous carbon, woven carbon fibers, and combinations of one or more of the foregoing.
US Pat. No. 10,245,253

PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST

ACTELION PHARMACEUTICALS ...

1. A pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is dimethyl fumarate.
US Pat. No. 10,246,533

HYDROPHILIC POLYMERIC PARTICLES AND METHODS FOR MAKING AND USING SAME

LIFE TECHNOLOGIES AS, Os...

1. A method of sequencing a polynucleotide, the method comprising:providing a device including an array of wells, at least one well operatively connected to an ion sensitive field effect transistor and including a hydrogel particle, the hydrogel particle being attached to a polynucleotide,
applying a solution including nucleotides of a predetermined type to the device; and
observing an ionic response to the applying the solution,
the hydrogel particle formed by:
in a disperse phase within an aqueous suspension, polymerizing a plurality of monomer units of a hydrophilic monomer having a hydrophobic protection group, thereby forming a polymeric particle including a plurality of the hydrophobic protection groups; and
converting the polymeric particle to the hydrogel particle, wherein converting the polymeric particle includes removing at least a portion of the plurality of the hydrophobic protection groups from the polymeric particle.
US Pat. No. 10,249,863

MICROPOROUS MATERIAL AND A METHOD OF MAKING SAME

Daramic, LLC, Charlotte,...

1. A microporous membrane comprising:a mixture of ultrahigh molecular weight polyethylene (UHMWPE) and filler in a weight ratio of filler to UHMWPE in a range of 1:9 to 15:1, the membrane having a plurality of micropores, a porosity in the range of 30-80%, and a machine direction (MD) tensile strength of greater than 25 N/mm2 when said membrane has a thickness in a range of 17.8 to 71.1 micrometers, said membrane being a stretched and subsequently calendered membrane and having a pore size distribution where an average pore diameter is in a range of 0.01 to 0.60 micrometers and no pore with a pore size greater than 1 micron,
wherein the membrane is at least one layer of a battery separator.
US Pat. No. 10,246,791

ELECTRODEPOSITION MEDIUMS FOR FORMATION OF PROTECTIVE COATINGS ELECTROCHEMICALLY DEPOSITED ON METAL SUBSTRATES

General Cable Technologie...

1. An article comprising:an electrically conductive metal substrate and a protective coating, the protective coating electrochemically deposited from an electrodeposition medium comprising:
a silicon alkoxide;
one or more quaternary ammonium compounds or quaternary phosphonium compounds, wherein the one or more quaternary ammonium compounds or quaternary phosphonium compounds are selected from the group consisting of tetra butyl ammonium hydroxide, benzyl triethyl ammonium hydroxide, tetra ethyl ammonium hydroxide, tetra methyl ammonium hydroxide, benzyl trimethyl ammonium hydroxide, trimethyl hydroxyethyl ammonium hydroxide, tetra butyl phosphonium hydroxide, benzyl triethyl phosphonium hydroxide, tetra ethyl phosphonium hydroxide, tetra methyl phosphonium hydroxide, benzyl trimethyl phosphonium hydroxide, and trimethyl hydroxyethyl phosphonium hydroxide; and
water;
wherein the article is at least one of one or more electrically conductive wires in an overhead conductor.
US Pat. No. 10,245,257

ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES

Dow Pharmaceutical Scienc...

1. A method of treating onychomycosis comprising applying a pharmaceutically acceptable efinaconazole formulation once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue in the treatment area initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period,wherein the efinaconazole formulation comprises 10% w/w efinaconazole, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate,
wherein the amounts of butylated hydroxytoluene and disodium edetate are sufficient to ensure the formulation is (i) colorless upon initial manufacturing of the formulation and (ii) colorless or pale yellow after storage for three weeks at a temperature of about 40° C.,
wherein the average amount of efinaconazole delivered to each cm2 of the treatment area is about 0.15 mg/cm2 to about 0.45 mg/cm2,
and wherein applying the formulation results in a mean plasma Cmax in a population of at least 15 adult onychomycosis patients after 28 days of once daily treatment that is less than 0.8 ng/mL.
US Pat. No. 10,246,537

RESIN COMPOSITION CONTAINING ETHYLENE-VINYL ALCOHOL COPOLYMER, MOLDED PRODUCT, AND MULTILAYER STRUCTURE

KURARAY CO., LTD., Kuras...

1. A resin composition, comprising:an ethylene-vinyl alcohol copolymer (A); and
a block copolymer (B) comprising a block (b1) that includes a vinyl aromatic monomer unit and a block (b2) that includes an isobutylene unit,
wherein:
the ethylene-vinyl alcohol copolymer (A) and the block copolymer (B) form a co-continuous phase structure;
a DSC curve obtained by cooling the resin composition at a rate of 50° C./min after heating the resin composition up to a melting point in a differential scanning calorimetry analysis shows two peaks, with a higher peak top temperature falling within a range of 130° C. or greater and 170° C. or less, and a lower peak top temperature falling within a range of 100° C. or greater and less than 130° C.; and
a mass ratio of the ethylene-vinyl alcohol copolymer (A) to the block copolymer (B) is 52/48 or greater and 63/37 or less.
US Pat. No. 10,246,538

PHOTOCURABLE RESIN COMPOSITION, CURED PRODUCT OF SAME AND METHOD FOR PRODUCING CURED PRODUCT

THREE BOND CO., LTD., Ha...

1. A photocurable resin composition comprising the following component (A) to component (D):component (A): a leuco dye;
component (B): a photoacid generating agent;
component (C): a radical polymerizable compound; and
component (D): an ?-hydroxy acetophenone-based radical initiator having thermal decomposition temperature of 200° C. or higher.
US Pat. No. 10,249,869

METHOD OF PRODUCING ELECTRODE BODY AND METHOD OF PRODUCING BATTERY

TOYOTA JIDOSHA KABUSHIKI ...

1. A method of producing an electrode body in which a first electrode plate having a structure including an electrode active material layer on a surface of a collecting foil and an insulating particle layer on a surface of the electrode active material layer, and a second electrode plate are laminated to obtain an electrode body of a battery, the method comprising:obtaining a state in which the electrode active material layer is present on the collecting foil, wherein the electrode active material layer is in a wet state, the electrode active material layer includes a first solid component containing electrode active material particles, and further includes a first liquid phase component that is volatilized by drying, and wherein a weight ratio of the first solid component in the electrode active material layer in the wet state being in a range of 70 to 85%; and
applying an insulating particle paint onto the electrode active material layer in the wet state, the insulating particle paint including a second solid component containing insulating particles and further including a second liquid phase component that is volatilized by drying, and a weight ratio of the second solid component in the insulating particle paint being in a range of 35 to 50%, wherein
a surface tension value of the first liquid phase component is in a range of 90 to 110% of a surface tension value of the second liquid phase component, and
when the insulating particle paint is applied onto the electrode active material layer in the wet state, a contact angle of the insulating particle paint on the electrode active material layer in the wet state is in a range of 10 to 40°.
US Pat. No. 10,244,750

INSECT PEST-TARGETING GEL COMPOSITION AND SUSTAINED RELEASE PREPARATION COMPRISING THAT

Shin-Etsu Chemical Co., L...

1. An insect pest-targeting gel composition comprising:one or more volatile substances and
an oil gelling agent,wherein the one or more volatile substances are comprised in an amount of from 70.0 to 99.0% by weight by the insect pest-targeting gel composition,wherein the oil gelling agent is selected from the group consisting of a long-chain fatty acid, a dextrin fatty acid ester, a sucrose fatty acid ester, a fructooligosaccharide fatty acid ester, a benzylidene derivative of sorbitol, and wax, andwherein the oil gelling agent is not a polyvalent metal salt of a long-chain fatty acid or 12-hydroxystearic acid.
US Pat. No. 10,245,006

COMPOSITION FOR ACOUSTIC-WAVE PROBE, AND SILICONE RESIN FOR ACOUSTIC-WAVE PROBE, ACOUSTIC-WAVE PROBE AND ULTRASONIC PROBE USING THE SAME, AS WELL AS DEVICE FOR MEASURING ACOUSTIC WAVE, ULTRASONIC DIAGNOSIS DEVICE, DEVICE FOR MEASURING PHOTO ACOUSTIC WAVE

FUJIFILM Corporation, To...

1. An acoustic-wave probe, comprising at least one selected from the group consisting of an acoustic lens and an acoustic matching layer, which comprise a silicone resin for an acoustic-wave probe, in which a composition for an acoustic-wave probe is hardened,the composition for an acoustic-wave probe comprising a polysiloxane mixture, and wherein the polysiloxane mixture comprises: a polysiloxane having a vinyl group; a polysiloxane having at least two Si—H groups in the molecular chain thereof; and silica particles having an average primary particle size of less than 12 nm.
US Pat. No. 10,246,542

ATACTIC POLYPROPYLENE COMB BLOCK POLYOLEFINS USEFUL AS MODIFIERS IN POLYOLEFINS AND HYDROCARBONS

ExxonMobil Chemical Paten...

1. A process for preparing comb-block polyolefins comprising:contacting, at a temperature within a range from 20 to 70° C., propylene with a first metallocene precursor and an activator to form vinyl-terminated atactic polypropylene having a weight average molecular weight of at least 8000 g/mole and a crystallinity of less than 20%;
contacting in a subsequent step, at a temperature within a range from 40 to 150° C., the vinyl-terminated atactic polypropylene with ethylene, propylene, or both, a second metallocene precursor, and an activator to form a comb-block polyolefin; and
forming in said subsequent step a linear low molecular weight component (LLMW) comprising ethylene or ethylene/propylene copolymers and having a number average molecular weight within a range from 7,000 to 50,000 g/mole,
wherein the comb-length of the comb-block polyolefin is greater than the entanglement molecular weight of atactic polypropylene.
US Pat. No. 10,244,751

WATER TEMPERATURE AS A MEANS OF CONTROLLING KINETICS OF ONSITE GENERATED PERACIDS

Ecolab USA Inc., Saint P...

1. A method of cleaning using an on-site generated peroxycarboxylic acid composition comprising:obtaining a peroxycarboxylic acid composition formed on-site using an adjustable biocide formulator or generator system; and
applying said peroxycarboxylic acid composition to sanitize, bleach and/or disinfect a surface in need thereof,
wherein the adjustable biocide formulator or generator system comprises:
a perhydrolysis reaction between an ester of a polyhydric alcohol and a C1 to C18 carboxylic acid, a source of alkalinity and an oxidizing agent to form the peroxycarboxylic acid composition;
an apparatus for producing the peroxycarboxylic acid composition that is insensitive to environmental temperatures of the location of the apparatus and/or one or more reagents of the perhydrolysis reaction comprising a reaction vessel and/or reaction manifold, a series of feed pumps, an outlet for dosing the peroxycarboxylic acid composition from said reaction vessel and a controller for a user- or system-inputted selection device; and
a temperature controlled mechanism for maintaining a controlled temperature of said reaction vessel and/or reaction manifold and/or one or more reagents to a temperature between about 4.4° C. to about 60° C.,
wherein said feed pumps are in fluid connection with said reaction vessel and/or reaction manifold and supply the one or more reagents to produce said peroxycarboxylic acid composition in said reaction vessel and/or reaction manifold;
wherein the said peroxycarboxylic acid composition is free of acid catalyst for the perhydrolysis reaction; and
wherein said reaction vessel and/or reaction manifold is in fluid connection with said outlet to dispense said peroxycarboxylic acid composition.
US Pat. No. 10,246,543

HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF

Novartis AG, Basel (CH)

1. A silicone hydrogel contact lens comprising a crosslinked polymeric material which comprises:units of a hydrophilized polydiorganosiloxane vinylic crosslinker which comprises (1) a polydiorganosiloxane polymer chain comprising dimethylsiloxane units and siloxane unit having one methyl substituent and one monovalent C4-C40 organic radical substituent having two to six hydroxyl groups, wherein the molar ratio of the hydrophilized siloxane units to the dimethylsiloxane units is from about 0.035 to about 0.15 and (2) two terminal (meth)acryloyl groups, wherein the polydiorganosiloxane vinylic crosslinker has a number average molecular weight of from about 3000 Daltons to about 80,000 Daltons;
units of a siloxane-containing vinylic monomer; and
units of at least one hydrophilic vinylic monomer,wherein the silicone hydrogel contact lens, when being fully hydrated, has an oxygen permeability (Dk) of at least about 70 barrers, a water content of from about 25% to about 70% by weight, and an elastic modulus of from about 0.2 MPa to about 1.2 MPa.
US Pat. No. 10,246,800

METHOD FOR MANUFACTURING POLYESTER FABRIC FOR AIRBAG

KOLON INDUSTRIES, INC., ...

1. A method for manufacturing a polyester fabric for an airbag, the method comprising:applying a polyester-based sizing agent to a polyester yarn;
manufacturing a textile substrate with the sizing agent-applied polyester yarn;
removing the sizing agent from the textile substrate under an alkaline condition of pH 8 to 10 to give a sizing agent-removed textile substrate; and
forming a coating layer on the sizing agent-removed textile substrate in order to enhance air-tightness,
wherein the removing the sizing agent comprises having the textile substrate pass through a scouring solution of pH 8 to 10;
wherein the scouring solution comprises
water; and
an alkaline compound, a permeating agent, an insolubilizing agent, and desizing agent, all of which are dissolved in the water; and
wherein the amount of the alkaline compound is from about 0.073 wt % to about 0.13 wt % to the total weight of the scouring solution.
US Pat. No. 10,244,753

HERBICIDAL COMPOSITION

SUMITOMO CHEMICAL COMPANY...

1. A herbicidal composition comprising saflufenacil and 2,4-D choline salt, wherein the weight ratio of saflufenacil to 2,4-D choline salt is from 1:0.5 to 1:100.
US Pat. No. 10,244,755

FUNGICIDAL ACTIVE COMPOUND COMBINATIONS

BAYER CROPSCIENCE AKTIENG...

9. A method of controlling phytopathogenic fungi comprising treating a seed or a plant with a fungicide and a safener, wherein the safener is mefenpyr diethyl and wherein the fungicide is tebuconazole, wherein the mefenpyr diethyl and the tebuconazole are applied to the seed or plant in synergistic amounts, wherein the weight ratio of mefenpyr diethyl to tebuconazole is from 50:1 to 1:50.
US Pat. No. 10,245,268

TREATMENT OF ACVR1-MEDIATED DISEASES

Sierra Oncology, Inc., P...

1. A method of treating an ACVR1-mediated disease comprising administering momelotinib or a pharmaceutically acceptable salt or solvate thereof to a patient in need thereof, wherein the ACVR1-mediated disease is selected from the group consisting of fibrodysplasia ossificans progressive (FOP) and diffuse intrapontine glioma (DIPG).
US Pat. No. 10,245,269

SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR

Epizyme, Inc., Cambridge...

1. A method of inhibiting the histone methyltransferase activity of EZH2 in a subject in need thereof comprising administering to the subject an effective amount of a solid crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide, wherein the solid crystalline form exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at about 3.9+/?0.3 degrees, about 17.5+/?0.3 degrees, and about 22.0+/?0.3 degrees 2-theta.
US Pat. No. 10,246,549

FAST CURE EPOXY RESINS AND PREPREGS OBTAINED THEREFROM

HEXCEL HOLDING GMBH, Pas...

1. A composition comprising a semisolid epoxy resin containing a curative dispersed therein, said curative having a particle size such that at least 90% of the particles have a size below 25 ?m at ambient temperature of 21° C., as determined in accordance with ASTM D1214, wherein the composition further comprises a diluent; said diluent comprising a particulate filler selected from micro balloons, glass, carbon, metal and/or combinations of the aforesaid fillers;and wherein, said composition further comprises a fibrous material, comprising a fleece.
US Pat. No. 10,244,758

COMPOSITIONS COMPRISING A GERMINANT AND AN ANTIMICROBIAL AGENT

Insight Health Limited, ...

1. A method of sterilising or disinfecting an abiotic surface such that it is essentially free of pathogens, the method comprising: contacting the abiotic surface with an antiseptic composition comprising a germinant and an antimicrobial agent, wherein the germinant comprises sodium taurocholate and at least two amino acids selected from the group consisting of histidine, arginine, aspartic acid, glycine and valine, and wherein the antimicrobial agent comprises benzalkonium chloride and benzyl alcohol;wherein the abiotic surface is contacted for a sufficient time for the pathogens to germinate and be killed;
wherein the antimicrobial agent is provided in an amount of from 0.01% to 2%;
wherein the amino acids are in an amount of from about 10 to about 100 mM based on the final composition;
wherein the antiseptic composition prevents sporulation of vegetative cells.
US Pat. No. 10,246,806

ECONOMICAL FIRE BARRIER NONWOVEN

TINTORIA PIANA US, INC., ...

1. A fire barrier nonwoven, comprising:10-80 wt % of at least one flame retardant (FR) cellulosic fiber, wherein said at least one FR cellulosic fiber contains or is treated with FR chemicals or FR compounds having a melting point or decomposition temperature at 400° C. (752° F.) or below; and
10-80 wt % of at least one untreated cellulosic fiber, said at least one untreated cellulosic fiber being the same or different cellulosic fiber used to make said FR cellulosic fiber,
wherein said at least one untreated cellulosic fiber is selected from the group consisting of cotton, kapok, flax, ramie, kenaf, abaca, coir, hemp, jute, sisal, pineapple, rayon, lyocell, and bamboo, and
wherein said at least one FR cellulosic fiber and said at least one untreated cellulosic fiber are assembled together as a fiber barrier nonwoven material.
US Pat. No. 10,249,879

BINDER COMPOSITION FOR SECONDARY BATTERY ELECTRODE-USE, SLURRY COMPOSITION FOR SECONDARY BATTERY ELECTRODE-USE, ELECTRODE FOR SECONDARY BATTERY-USE AND PRODUCTION METHOD THEREFOR, AND SECONDARY BATTERY

ZEON CORPORATION, Chiyod...

1. A binder composition for secondary battery electrode-use comprisinga particulate binding material and water, wherein
the particulate binding material includes a first particulate polymer having a degree of swelling of at least 450 mass % and no greater than 700 mass % and containing an aliphatic conjugated diene monomer unit and an aromatic vinyl monomer unit, and a second particulate polymer having a degree of swelling of at least 300 mass % and no greater than 400 mass % and containing a (meth)acrylic acid ester monomer unit,
wherein the degree of swelling is measured using an electrolyte solution obtained by dissolving LiPF6 with a concentration of 1.0 M in a mixed solvent of ethylene carbonate and ethyl methyl carbonate with a volume ratio of 3/7 and vinylene carbonate with a solvent ratio of 2 mass %.
US Pat. No. 10,244,759

USE OF FORCHLORFENURON FOR PROMOTING PLANT GROWTH

KIM-C1, LLC, Fresno, CA ...

1. A method of promoting root growth of a plant, the method comprising contacting the plant, or a seed of the plant, with a composition comprising forchlorfenuron (CPPU) before the reproductive growth stage of the plant, such that either the root length of the plant is at least 5% greater than for an untreated plant, or the ratio of root length to stem length is increased by at least 5% compared to the untreated plant, wherein the plant is a member of the genus Gossypium, wherein the concentration of CPPU in the composition is from about 2 to about 50 ppm when the plant is contacted, and wherein the concentration of CPPU in the composition, is from about 25 to about 1000 ppm in the composition when the seed is contacted.
US Pat. No. 10,245,272

TRANSMEMBRANE PENETRATION ENHANCER

1. A method for delivering an active agent through the skin of a patient in need thereof, said method comprising contacting the skin of said patient with a transmembrane penetration enhancer consisting of said active agent, wherein said transmembrane penetration enhancer is a thermotropic liquid crystal transmembrane penetration enhancer consisting of:1) one or a fused mixture of two or more cholesteryl esters in an amount of 90% or more; and
2) an active agent selected from the group consisting of diazepam, oxazepam, lorazepam, clonazepam, bromazepam, alprazolam, clotiazepam, clobazam, buspirone, amphetamine, methamphetamine, methylphenidate, cathine, fenfluramine, piracetam, and meclofenoxate, in an amount of 10% or less;wherein said thermotropic liquid crystal transmembrane penetration enhancer delivers said active agent through the skin of the patient when said cholesteryl esters are in a mesomorphic state.
US Pat. No. 10,244,761

METHOD OF USING CARBON NANOTUBES TO AFFECT SEED GERMINATION AND PLANT GROWTH

Board of Trustees of the ...

1. A method of enhancing growth of a plant comprising the steps of: (a) spraying a composition of matter on the stems or leaves of a plant, wherein said composition comprises water and an effective concentration of carbon nanomaterials in the range of 0.1-200 ?g/mL, wherein said carbon nanomaterials comprises single-walled nanotubes, multi-walled nanotubes, nanofibers, or fullerenes; and (b) selecting a plant having an increased number of flowers as compared to a non-treated plant.
US Pat. No. 10,245,273

ORAL PHARMACEUTICAL PRODUCTS AND METHODS OF USE COMBINING TESTOSTERONE ESTERS WITH HYPOLIPIDEMIC AGENTS

Clarus Therapeutics, Inc....

1. A oral pharmaceutical composition comprising:a. a hypolipidemic agent that is a peroxisome proliferator activating receptor (PPAR) agonist; and
b. 18 to 22 percent by weight of solubilized testosterone undecanoate, solubilized in a carrier comprising
i. 15 to 17 percent by weight of hydrophilic surfactant;
ii. 50 to 55 percent by weight of lipophilic surfactant; and
iii. 10-15 percent by weight of a mixture of borage oil and peppermint oil.
US Pat. No. 10,244,762

SOLID AQUATIC ORGANISM CONTROL COMPOSITION AND METHOD OF USE

Arch Chemicals, Inc., Al...

1. A solid aquatic organism control composition comprising:a hydrogen peroxide producing compound capable of releasing hydrogen peroxide when contacted with an aqueous medium;
a chelating agent comprising an aminocarboxylate;
a peroxide enhancing agent comprising a carboxylic acid or salt thereof, a hydroxyl-containing compound, a compound containing a cuprous ion, or combinations thereof; and
wherein the hydrogen peroxide producing compound is present in the composition in an amount greater than or equal to about 85% by weight and the chelating agent is present in the composition in an amount of from about 0.1% to about 1.5% by weight.
US Pat. No. 10,245,274

CHITOSAN-BASED MATRICES AND USES THEREOF

THE TRUSTEES OF THE UNIVE...

1. A method of treating an otorhinolaryngology-associated pathology, or Head and Neck associated pathology in a subject, comprising administering through the auditory bulla a composition onto the round window membrane of the subject for release of an agent to the perilymph of the inner ear of the subject, wherein said composition comprises a solution of chitosan-glycerophosphate (CGP) and the agent, wherein the agent dissolved therein is present in an amount effective in the treatment of the otorhinolaryngology-associated pathology, or Head and Neck associated pathology, wherein auditory functions are preserved by said administering.
US Pat. No. 10,244,763

ANTIBACTERIAL LAYER-ATTACHED BASE MATERIAL, ANTIBACTERIAL SHEET, RADIATION PHOTOGRAPHING DEVICE, AND TOUCH PANEL

FUJIFILM Corporation, Mi...

1. An antibacterial layer-attached base material comprising:a base material; and
an antibacterial layer which is disposed on at least a part of the surface of the base material,
wherein the antibacterial layer contains at least one antibacterial agent containing silver,
wherein the amount of silver ions per a unit area measured in the following extraction test is 15.8 to 40 ng/cm2,
wherein, in the extraction test, the amount of silver ions per a unit area is obtained by using a 1/500 common broth medium defined in JIS Z 2801:2010 as an extraction liquid, controlling the temperature of the extraction liquid so as to be at 35±1° C., bringing the extraction liquid into contact with the antibacterial layer in the antibacterial layer-attached base material for an hour, measuring the amount of silver ions extracted in the extraction liquid, and dividing the obtained value by the contact area of the antibacterial layer with respect to the extraction liquid; the unit of the amount of silver ions is ng; the unit of the contact area is cm2; and the unit of the amount of silver ions per a unit area is ng/cm2,
wherein the antibacterial layer is formed by subjecting a curable composition containing at least a monomer having a polyoxyalkylene group and a polymerizable group and the antibacterial agent to a curing treatment,
wherein the mass percentage of the antibacterial agent with respect to the mass of the total solid content of components of the cured material in the antibacterial layer is between 0.5% and 2.0%,
wherein the antibacterial layer in the form of a film with a thickness of 4.0 ?m to 5.0 ?m, and
wherein the water contact angle is between 20° and 25°.
US Pat. No. 10,244,764

GREEN PLANTS TREATED WITH TIO2 TO REMOVE CONTAMINANTS IN AIR

Imam Abdulrahman Bin Fais...

1. A method of reducing contaminants in air, comprising:applying a titanium dioxide-containing growth media to at least one of a root, stem, and leaf of a Myrtus communis plant, and growing the Myrtus communis plant, wherein the growth media is a liquid growth media, a gel growth media, or both to form a titanium dioxide-containing Myrtus communis plant;
exposing the titanium dioxide-containing Myrtus communis plant to contaminant-containing air comprising at least one contaminant selected from the group consisting of CO2, SO2, formaldehyde, CO, benzene, toluene, xylene, and ethyl benzene, wherein a contaminant concentration in the contaminant-containing air is reduced by 10% to 98% relative to a contaminant concentration in the contaminant-containing air prior to the exposing.
US Pat. No. 10,245,276

CO-CRYSTALS OF TRAMADOL AND COXIBS

LABORATORIOS DEL DR. ESTE...

1. A co-crystal comprising (rac)-tramadol.HCl and celecoxib in a molecular ratio of 1:1, characterized in that it has an orthorhombic unit cell with the following dimensions:a=11.0323(7) ?
b=18.1095(12) ?
c=17.3206(12) ?.
US Pat. No. 10,244,765

INHIBITING OR REDUCING FUNGAL GROWTH

Georgia State University ...

1. A method for inhibiting or reducing fungal growth in grain, comprising exposing the grain to a composition comprising one or more bacteria, wherein the one or more bacteria are selected from the group consisting of Rhodococcus rhodochrous DAP 96253, Rhodococcus rhodochrous DAP 96622, Rhodococcus erythropolis, and combinations thereof, and wherein the one or more bacteria are provided in a quantity sufficient to inhibit or reduce fungal growth on the grain.
US Pat. No. 10,245,277

COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION

VOLANT HOLDINGS GMBH, (C...

1. A method of treating hepatic steatosis in a patient comprising orally administering an effective amount of an ileal brake composition in an oral dosage form comprising an ileal brake compound wherein at least 50% by weight of the ileal brake compound administered to said patient is released in the ileum of the patient.
US Pat. No. 10,245,789

HYBRID COMPONENT PART COMPRISING A LOCAL STIFFENING COMPOSED OF A TWO-STAGE-CROSSLINKED POLYURETHANE-BASED FIBRE COMPOSITE MATERIAL

Evonik Degussa GmbH, Ess...

1. Process for producing a hybrid component part comprising the steps of:a) providing a reactive composition at least comprising:
at least one hardener which is a uretdione having an NCO functionality of at least two,
at least one binder which is a polyol compound having an OH functionality of 3 to 6 and which comprises at least one polar functional group selected from an ester, carbonate, amide, urethane, urea, thioester or thiocarbonate functionality;
b) providing fibres;
c) coating the fibres with the reactive composition;
d) exposing at least the reactive composition to heat to perform a first crosslinking reaction in the course of which hardener and binder are converted into a thermoplastic polymer, thus embedding the fibres into the thermoplastic polymer;
e) providing a metallic main body or a semifinished precursor thereof;
f) placing the thermoplastic polymer comprising the fibres embedded therein onto a localized area of the main body/semifinished precursor thereof;
g) pressing the thermoplastic polymer onto the main body/semifinished precursor thereof so that the fibres adhere to the main body/semifinished precursor thereof via the thermoplastic polymer;
h) forming the semifinished precursor comprising the thermoplastic polymer adherent thereto to afford the metallic main body provided that only a semifinished precursor of the main body was provided in step e);
i) exposing at least the thermoplastic polymer to heat to perform a second crosslinking reaction in the course of which the thermoplastic polymer is converted to a thermoset polymer;
k) obtaining the hybrid component part comprising at least the metallic main body provided with at least one local stiffening composed of a fibre composite material, wherein the fibre composite material comprises a matrix formed from the thermoset polymer and the fibres embedded therein,
wherein the thermoplastic polymer comprising the fibres embedded therein is provided in layerwise fashion, in that the layers are compressed to afford a stack in the absence of the main body/the semifinished precursor thereof and in that the sequence of steps f) and q) is effected by placing and pressing the stack onto the main body/the semifinished precursor thereof.
US Pat. No. 10,245,278

LIQUID OR SEMI-LIQUID PHARMACEUTICAL, DIETARY OR FOOD COMPOSITION FREE OF BITTERNESS CONTAINING AN ARGININE SALT

2. A liquid or semi-liquid, aqueous dietary, pharmaceutical composition, comprising at least one salt of L-arginine in an amount of at least one gram of said salt per unit dose, said composition comprising:from 15 to 30% by weight of L-arginine salt,
from 15 to 45% by weight of maltitol, and
from 0.1% to 12% by weight of an alcohol or of an alcoholate, relative to the total weight of the composition.
US Pat. No. 10,245,279

USE OF IMMOBILIZATION PARTICLES FOR REMOVAL OF MICROORGANISMS AND/OR CHEMICALS

NuBiome, Inc., Mountain ...

1. A method for immobilizing a target microorganism or target chemical found in a gastrointestinal tract of a mammal, the method comprising:introducing into a gastrointestinal tract of the mammal an immobilization particle comprising a flat substrate, one or more further structures disposed on one side of the flat substrate, and immobilization molecules attached to one or more portions of the one side of the flat substrate and not to the one or more further structures, which immobilization molecules being capable of attaching to the target microorganism or the target chemical; and
wherein the one or more further structures comprise columns having a height in a range from about 0.01 microns to about 500 microns and being spaced apart in a range from about 0.1 microns to about 500 microns.
US Pat. No. 10,246,559

METHOD FOR PREPARING SILICONE RESINS CONTAINING HYDROXY GROUPS AND ALKOXY GROUPS

WACKER CHEMIE AG, Munich...

1. A process for preparing silicone resins bearing hydroxy groups and alkoxy groups, comprising:reacting at a temperature of at least 50° C. and for at least 30 minutes,
a) 100 parts by weight of alkoxysilane,
b) from 0.01 to 1 parts by weight of hydrocarbon containing, based on alkoxysilane, from 10 to 2000 ppm by weight of Cl, and
c) water
without the addition of organic solvent(s) which at 0.1 MPa and 20° C. are soluble to a maximum extent of 1% by weight in water.
US Pat. No. 10,245,280

USE OF HYALURONIC ACID FOR PREPARING COMPOSITIONS FOR TREATING ORAL CAVITY APHTHAS

Bioplax Limited, London ...

1. A method of reducing the number of ulcers in a subject having an episode of Recurrent Oral Aphthous Ulcers (ROAU) said method comprising the steps of:selecting a subject having an episode of ROAU; and
administering, repeatedly to the selected subject, from the first day to the seventh day of the episode of ROAU, a composition comprising between 0.01 and 1% by weight hyaluronic acid or a salt thereof, said hyaluronic acid or salt thereof being the sole active ingredient and having an average molecular weight of between 800,000 and 4,000,000,
wherein said composition is administered in an amount sufficient to reduce the number of ulcers in the subject by the fifth day of said single episode.